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ABSTRACT 
 
 
Adenylyl cyclase (AC) catalyzes the formation of the ubiquitous second 
messenger cAMP.  AC isoforms differ in their tissue distribution, cellular localization, 
regulation, and protein interactions, and most cells express multiple isoforms.  We 
hypothesized that cAMP produced by different AC isoforms regulates unique cellular 
responses.  Overexpression of individual isoforms had distinct effects on forskolin (Fsk)-
induced expression of a number of known cAMP-responsive genes in human bronchial 
smooth muscle cells (BSMC) and human embryonic kidney cells (HEK-293).  Most 
notable, in BSMC overexpression and activation of AC2 enhanced interleukin 6 (IL-6) 
expression, but overexpression of AC3 or AC6 had no effect.  IL-6 production by BSMC 
was induced by Fsk and select G protein-coupled receptor (GPCR) agonists, though IL-6 
levels did not directly correlate with intracellular cAMP levels.  At low cAMP 
concentrations exchange protein directly activated by cAMP (Epac) predominated in 
mediating the IL-6 response, but at higher cAMP concentrations protein kinase A (PKA) 
assumed the larger role.  IL-6 promoter mutations demonstrated that activator protein 1 
(AP-1) and cAMP responsive element (CRE) transcription sites were required for cAMP 
mediated induction.  Our findings indicate that AC2 participates in a cAMP-signaling 
compartment that specifically regulates IL-6 expression in BSMC and that other AC 
isoforms are excluded from this compartment. 
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CHAPTER 1.    INTRODUCTION 
 
 
G protein-coupled receptors (GPCR) are one of the most utilized targets for 
therapeutic drugs, with up to 50% of pharmaceuticals acting at these receptors (Salon et 
al. 2011).  Stimulation of a receptor results in generation of second messengers such as 
cyclic adenosine monophosphate (cAMP), inositol trisphosphate (IP3), and 
diacylglycerol, and then signal transduction proceeds through a wide range of 
downstream effectors.  GPCR regulate numerous physiological responses depending on 
the ligand, receptor, and cell-type.  With few second messengers initiating a huge array of 
potential responses, cells must have mechanisms in place to direct the proper response 
upon agonist binding, however the mechanisms responsible are poorly understood.  We 
are interested in how cells integrate and separate common signaling pathways and 
produce distinct responses.  We hypothesize that signaling compartments are essential for 
directing specific cellular responses from a given GPCR. A better understanding of 
intracellular signaling compartments could allow for more specifically targeted 
therapeutics.   
 
 
Bronchial Smooth Muscle and Asthma 
 
Bronchial smooth muscle cells (BSMC) are critical in the pathogenesis and 
treatment of asthma.  They possess secretory and contractile properties and are involved 
in the airway hyper-responsiveness, constriction, and remodeling that occur in asthma 
(Tliba and Panettieri 2009).  In asthmatics there is an increase in both the size and 
number of airway smooth muscle cells (James et al. 2012).  Asthmatic BSMC produce 
and secrete higher levels of inflammatory cytokines and extra cellular matrix proteins, 
contributing to inflammation and remodeling (Oliver et al. 2006; Johnson et al. 2004).  It 
has been debated whether the pro-inflammatory environment of the asthmatic airway or 
changes to the cells themselves are responsible for alterations in the structure and 
function of airway smooth muscle (ASM) in asthma, and there is evidence that both play 
a role (Shore 2004).  Bronchoalveolar lavage fluid (BALF) from allergen-challenged 
asthmatics causes increased proliferation of normal BSMC in culture, suggesting that the 
environment could be responsible for some of the phenotypic changes observed in asthma 
(Naureckas et al. 1999).  A number of studies have also shown intrinsic differences in 
BSMC from asthmatic and nonasthmatic airways (Yeganeh et al. 2013). In vitro BSMC 
from asthmatic donors show greater contractility in response to histamine (Matsumoto et 
al. 2007).  Genetic changes have also been observed that might explain phenotypic 
differences in BSMC of asthmatics (Oliver et al. 2006; Martin and Jo 2008; Roth et al. 
2004). 
 
GPCR signaling pathways, key to the pathogenesis and treatment of asthma, are 
also altered in BSMC of asthmatics.  An imbalance of pro-contractile to pro-relaxant 
signaling occurs in asthma (Billington and Penn 2003).  β-adrenergic receptor (βAR) 
agonists are less potent inducers of relaxation in carbachol contracted bronchial strips 
from asthmatic donors, suggesting reduced number or activity of the receptors (Goldie et 
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al. 1986).  Polymorphisms in β2AR have been shown to enhance receptor down-
regulation and may increase the propensity to develop certain types of asthma (Small et 
al. 2003; Turki et al. 1995). In addition to changes at the level of the receptor, 
phosphodiesterase (PDE) 4 expression and activity is increased in asthmatic BSMC, thus 
reducing cAMP signaling and further shifting the balance toward contraction (Trian et al. 
2011).  The shift in the balance of contractile to relaxant signaling may contribute to 
development and severity of asthma.  
 
Airway constriction associated with asthma is treated with βAR agonists, which 
stimulate smooth muscle relaxation and bronchodilation largely through cAMP signaling 
pathways. Intermittent asthma can be treated at the time of exacerbation with short-acting 
βAR agonists for rapid bronchodilation.  In moderate or severe asthma, in addition to 
short-acting βAR agonists as needed, long-acting βAR agonists are used in combination 
with inhaled corticosteroids as maintenance therapy (National Asthma and Prevention 
2002). βAR agonists cause relaxation by activating cAMP signaling pathways and 
potassium channel activity, but they can also initiate several other responses, and some 
are detrimental to the asthmatic airway as discussed below.  
 
 
GPCR and cAMP Signaling  
 
GPCR are membrane-spanning proteins with extracellular ligand binding pockets 
and intracellular coupling to G-proteins.  When a hormone, neurotransmitter, or drug 
binds to a GPCR on the cell surface, it initiates an intracellular signaling cascade. Ligand 
binding to the GPCR results in a conformational change of the receptor and interactions 
with G-proteins leading to GTP exchange and dissociation of the heterotrimeric G protein 
into Gα and Gβγ subunits.  G-proteins have particular effects depending on their subtype.  
Gαs stimulates and Gαi inhibits activity of adenylyl cyclase (AC), the enzyme that 
catalyzes the formation of cAMP from adensine triphosphate (ATP).  Gαq activates 
phospholipase C (PLC) that initiates pathways involved in phospholipid and Ca2+ 
signaling though IP3 and diacylglycerol (Pierce et al. 2002).  Each cell can express many 
GPCR, allowing it to respond to a variety of stimuli (Insel et al. 2012). In BSMC, GPCR 
signaling regulates cell cycle progression, contraction (Gαq, Gαi) and relaxation (Gαs), and 
gene expression, among many other processes (Billington and Penn 2003).  
 
Following Gαs stimulation, AC catalyze the formation of cAMP from ATP.  
cAMP regulates many cellular processes by activating protein kinase A (PKA) and 
exchange protein directly activated by cAMP (Epac) (Walsh et al. 1968; de Rooij et al. 
1998).  cAMP signaling is important in the treatment of asthma, because it causes 
relaxation of BSMC and dilation of the airway.  Upon activation by cAMP, PKA 
phosphorylates several targets that lead to relaxation of smooth muscle cells (Knox and 
Tattersfield 1995). Calcium is the primary mediator of contraction, and cAMP signaling 
pathways oppose contractile pathways by regulating intracellular calcium concentrations 
and calcium sensitivity of contractile machinery.  cAMP inhibits IP3-mediated Ca2+ 
release and facilitates Ca2+ uptake by the sarcoplasmic reticulum (Murthy 2001).  PKA-  
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mediated phosphorylation of phospholamban reduces intracellular calcium by relieving 
phospholamban’s inhibition of sarcoplasmic reticulum calcium pump ATPase channels 
(Prakash et al. 1997; Simmerman et al. 1986).  Smooth muscle contraction occurs via 
myosin cross bridge cycling, and PKA plays a role in regulating the process.  
Phosphorylation of myosin light chain increases interactions with actin and ATPase 
activity and results in contraction.  PKA phosphorylation promotes relaxation by 
decreasing the activity of myosin light chain kinase and increasing activity of myosin 
light chain phosphatase (Conti and Adelstein 1981; Pfitzer 2001; Wooldridge et al. 2004).  
Gαs and PKA also facilitate βAR-mediated relaxation by activating potassium channels 
(Kume et al. 1994). The pro-relaxant actions of cAMP are taken advantage of in the 
treatment of asthma by βAR agonist therapies.  
 
 
βAR Agonists  
 
βAR agonists activate the cAMP signaling pathways described above and are 
used for bronchoprotection and as rescue treatment in asthma.  The goal of βAR agonist 
therapy is to cause relaxation of smooth muscle and bronchodilation through Gαs and 
cAMP signaling, but βAR agonists can also induce other signaling pathways that are not 
favorable in the asthmatic airway. Two main downsides of βAR agonists are changes in 
βAR coupling and desensitization.  β2AR that initially couple to Gαs can undergo G-
switching upon exposure to agonist (Daaka et al. 1997b).  Switching to Gαi coupling leads 
to activation of mitogen activated protein kinase (MAPK) cascades that induce 
expression of pro-inflammatory genes and can worsen asthma (Pelaia et al. 2005).  β2AR 
can also exhibit atypical coupling to Gαq, which increases Ca2+ and contractile responses 
(Anderson 2006).  Chronic βAR agonist exposure leads to tolerance and desensitization 
(Cooper et al. 2011; Benovic et al. 1985).  Several mechanisms can play a role in 
desensitization and downregulation of βAR following stimulation, which result in 
decreased responsiveness to therapy over time (Lohse et al. 1990; Giembycz and Newton 
2006).  Phosphorylation by PKA reduces receptor affinity for Gαs and increases affinity 
for Gαi (G switching) (Daaka et al. 1997a).  Phosphorylation by G protein coupled-
receptor kinase (GRK) recruits β arrestin and facilitates internalization of the receptor via 
clathrin-coated pits (Benovic et al. 1988).  Due to altered coupling and responsiveness of 
βAR, treatment with βAR agonists alone can lead to increased hyperresponsiveness and 
inflammation, reduced bronchodilation, and even increased risk of morbidity and 
mortality (Cheung et al. 1992; Johnston and Edwards 2009; Strandberg et al. 2007).  In 
the future AC may represent a better therapeutic target with fewer unintended effects, 
since only cAMP pathways would be activated without Gαi or Gαq activation.  
Approaches targeting AC also have the potential to create larger changes in cAMP, since 
AC is the limiting component in βAR-stimulated cAMP production(Ostrom et al. 2000b).     
 
 
cAMP Signaling Compartments 
 
cAMP is ubiquitous and mediates many responses in BSMC.  It would not be 
practical for cAMP to freely float around the cell activating numerous pathways in 
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response to each stimulus, and in fact steady state concentrations would likely not be high 
enough to activate PKA (Rich et al. 2000).  Compartmentalized cAMP signaling allows 
specific responses to stimuli.  The first examples of compartmentation of cAMP signals 
were described in myocardium where it was observed that of two agonists, epinephrine 
and prostaglandin E1 (PGE1) that act through cAMP and PKA, only epinephrine 
stimulated contractile force and glycogen phosphorylase activity (Keely 1977, 1979).  
Homogenate fractionation showed that these stimuli activated PKA in different 
compartments (Buxton and Brunton 1983).  Compartmentation involves components both 
upstream and downstream of cAMP production.  There are nine AC isoforms, which 
differ in their tissue distribution, regulation (Table 1-1), cellular localization, and 
associations with other proteins. We hypothesize that the differences among isoforms 
help them define unique cAMP compartments and lead to AC isoform-specific cellular 
and physiological responses.  
 
Several components in addition to AC contribute to establishment of cAMP 
signaling compartments.  PDE hydrolyze cAMP, limiting its diffusion from the site of 
production (Mika et al. 2012). A-kinase anchoring protein (AKAP) scaffolding molecules 
bring together multiple signaling molecules in complexes (Smith et al. 2006). Over 50 
AKAP have been described, and like AC they have unique tissue distribution, 
intracellular localization, and interactions (Dessauer 2009).  In addition to prearranging 
signal cascades, AKAP bind PDE and regulators of AC, keeping cAMP near the site of 
production. AKAP and direct complexes containing AC allow for rapid and precise 
signaling to generate specific cellular responses downstream of a given stimulus (Ostrom 
et al. 2012).  
 
Although specific physiological responses following activation of different Gαs 
receptors have been known since the 1970’s, AC isoform-specific responses have only 
recently been described.  AC5 and AC6, though similar in their structure and regulation, 
have been shown to have unique roles in the heart through overexpression and knockout 
studies (Pierre et al. 2009).  In cardiomyopathy models, AC6 overexpression increases 
survival and heart function (Roth et al. 2002).  Conversely, it is knockdown of AC5 that 
is cardioprotective (Vatner et al. 2009).  Differences in the localization and associations 
of AC5 and AC6 appear to drive the isoform-specific effects in cardiomyocytes.  AC6 is 
located outside T-tubules where it colocalizes with β2AR (Timofeyev et al. 2013).  AC6 
activation in response to βAR agonist results in increased L-type calcium current 
(Timofeyev et al. 2013).  AC5 on the other hand is localized to T-tubules where it is in a 
complex containing PDE, and cAMP diffusion is tightly constrained and unable to alter 
calcium currents (Timofeyev et al. 2013). Interestingly, even a catalytically inactive AC6 
mutant has been shown to have beneficial effects when overexpressed in mice with 
cardiomyopathy, likely by regulating Akt signaling through direct interactions with PH 
domain and Leucine rich repeat Protein Phosphatase 2 (Gao et al. 2009; Gao et al. 2011). 
The benefits of AC6 signaling in failing hearts are so promising that clinical trials are 
underway utilizing AC6 gene transfer in patients with congestive heart failure (Tang et al. 
2012).  Other examples of AC isoform-specific regulation of cellular responses have been 
described in vascular and airway smooth muscle.  In vascular smooth muscle, AC1 
mediates proliferation, while AC6 has no impact on proliferation but is involved in 
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Table 1-1. Isoform-specific regulation of adenylyl cyclases 
 
Regulator 
 
Effect AC subtype References 
G protein    
Gs Stimulation All Isoforms (Iyengar 1993) 
Gi Inhibition AC1, AC5, AC6; not AC2 (Taussig et al. 1993a) (Federman et al. 1992) (Chen and 
Iyengar 1993) (Taussig et al. 1994) 
Gβγ Inhibition AC1, AC5, AC6 (Taussig et al. 1993b) (Bayewitch et al. 1998) 
 Stimulation AC2, AC4  
Conditional AC5, AC6 
(Tang and Gilman 1991) (Gao and Gilman 1991) 
(Gao et al. 2007) 
    
Forskolin Stimulation All Isoforms (including AC9) (Onda et al. 2001) (Premont et al. 1996) (Cumbay and Watts 
2004) 
    
Calcium/Calmodulin    
Ca2+/CaM Stimulation AC1, AC3, AC8 (Tang et al. 1991) (Choi et al. 1992) (Cali et al. 1994) 
Ca2+ Inhibition AC5, AC6 (Yoshimura and Cooper 1992) (Katsushika et al. 1992) 
    
Kinase Regulation    
PKC Stimulation AC1, AC2, AC3, AC5, AC7 (Jacobowitz et al. 1993) (Jacobowitz and Iyengar 1994) (Bol 
et al. 1997) (Kawabe et al. 1994) (Watson et al. 1994) 
 Inhibition AC6 (Lai et al. 1997) 
PKA Inhibition AC5, AC6 (Iwami et al. 1995) (Chen et al. 1997) 
CaM Kinase Inhibition AC1, AC3 (Wayman et al. 1996) (Wei et al. 1996) 
Raf kinase Stimulation AC2, AC5, AC6  (Ding et al. 2004) 
 
Reprinted with permission. ????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????? ??????????????????????????????????????????????????
??????????????????????????? 
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With knowledge of differences among AC isoforms and compartmentalization of 
cAMP signaling, we hypothesized that BSMC possess AC isoform-specific regulation of 
cellular processes.  We examined regulation of cAMP-responsive genes in BSMC 
overexpressing individual AC isoforms and uncovered a number of genes that are 
regulated in an isoform-specific manner.  AC2-derived cAMP selectively regulates 
expression of the pro-inflammatory cytokine interleukin 6 (IL-6), a key contributor to the 
pathogenesis of asthma.  cAMP induces IL-6 production, but the levels of cAMP and 
IL-6 are not directly correlated.  AC2’s unique localization, regulation and interactions 
allow it to activate PKA and Epac in a signaling compartment associated with induction 
of IL-6.  AC6-derived cAMP is tied to regulation of other genes, but PDE limit this 
cAMP pool from activating components involved in IL-6 induction.  The cAMP 
compartments and signaling pathways responsible for stimulation of IL-6 transcription 
appear to be altered in asthma. βAR agonists currently represent the best therapy for 
treatment of bronchoconstriction in asthma, but some of the signaling pathways activated 
by βAR worsen inflammation and constriction.  Targeting AC directly instead of through 
βAR and Gαs would stimulate cAMP production without activation of Gαi and Gαq and 
could result in greater cAMP production. We show that cAMP can also mediate 
undesirable responses in BSMC, in particular induction of IL-6.  Since cAMP signaling is 
highly compartmentalized, therapeutics targeting AC6 may stimulate ASM relaxation and 
bronchodilation without inducing IL-6 production.  A greater knowledge of cAMP 
signaling compartments could allow highly targeted treatment for many diseases, 
including asthma.  
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CHAPTER 2.    METHODS 
 
 
Materials 
 
Forskolin (Fsk), isoproterenol (Iso), 3-isobutyl-1-methylxanthine (IBMX), 
Adenosine 5′-[γ-thio]triphosphate (ATPɣS), Arginine vasopressin (AVP), prostaglandin 
D2 (PGD2), glucagon, 5′-(N-Ethylcarboxamido)adenosine (NECA), calcitonin gene 
related peptide (CGRP), and substance P were purchased from Sigma; 8-Br-cAMP, 
8CPT-2Me-cAMP, GF 109203X, SB 202190, (±)-SKF-83566, SQ22,536 and 
wortmannin from Tocris, and butaprost (buta) from Cayman.   
 
Wild-type and mutant IL-6 promoter luciferase constructs were purchased from 
the Belgian Coordinated Collections of Micro-organisms/LMBP; LMBP acquisition 
numbers 4495, 4496, 4498, 4499, 4500 (Vanden Berghe et al. 1998; Plaisance et al. 
1997). Luciferase constructs contain 1168 bp of the human IL-6 promoter (wild-type or 
with point mutations in specific promoter elements) upstream of LUCm in pGL3-Basic 
vector. Binding sites were altered by site-directed mutagenesis to prevent transcription 
factor binding at the following promoter elements: 3’ or 5’ activator protein 1 (AP-1) site, 
cAMP response element (CRE), CCAAT-enhancer-binding proteins (C/EBP), or nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFκB) sites.          
 
 
Cell Culture 
 
Human BSMC purchased from Lonza were grown in smooth muscle basal 
medium supplemented with the SmGM-2 bullet kit (5% fetal bovine serum, 0.1% insulin, 
0.1% human epidermal growth factor, 0.2% human fibroblast growth factor-β ,and 
gentamicin sulfate/amphotericin B; Lonza).  Cells were kept at 5% CO2 and 37° C.  
Experiments were performed on cells from passage 5-13.  
 
Human embryonic kidney 293A cell line (HEK-293) purchased from Invitrogen 
were grown in  Dulbecco's Modified Eagle's medium (DMEM) (high glucose) with 10% 
fetal bovine serum, 0.1 mM MEM Non-Essential Amino Acids, 2 mM L-glutamine, and 
1% Pen-Strep.  Cells were kept at 5% CO2 and 37° C. 
 
 
AC Overexpression 
 
Adenoviral constructs expressing rat AC2, rat AC3, mouse AC6, or lacZ (control) 
cDNA were used for AC overexpression studies in BSMC.  The titer of AC virus was 
chosen to give similar global cAMP levels in response to 1 µM Fsk.  Cells were infected 
18-24 h before treatment.      
 
Plasmids encoding rat AC2, human AC6, or the empty pEGFP-n1 vector were 
used for overexpression studies in HEK-293.  Cells were transfected with Cal-Phos 
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calcium phosphate transfection kits (Clontech) 24 h after plating.  Cells were transfected 
with 3 µg plasmid per 60 mm dish.  For polymerase chain recaction (PCR) arrays Fsk 
was added 24 h after transfection and RNA was isolated 24 h later as described for PCR 
array below.  
 
 
PCR Array  
 
Following treatment cells were lysed and RNA was isolated using RNeasy kit 
with on-column DNase step (Qiagen).  RNA purity and yield were determined with 
Nanodrop spectrophotometer.  1 µg RNA was reverse transcribed using RT2 first strand 
kit (SABioscience).  cDNA from a single sample was combined with RT2 SYBR Green 
Master Mix (SABioscience) and distributed among wells of a multiwell plate containing 
gene specific and control primers on Human cAMP/Ca2+ PathwayFinder RT² Profiler™ 
or Human G Protein Coupled Receptors 384HT RT² Profiler™ PCR Array 
(SABioscience).  The crossing point (CP) was determined by the second derivative 
maximum algorithm on Roche Lightcycler 480, and fold change was calculated by ΔΔCP 
method.  Melt curve analysis was used to exclude any gene whose CP may have been 
artificially reduced by multiple amplification products.   
 
 
qRT-PCR 
 
For quantitative reverse transcriptase PCR (qRT-PCR) RNA was isolated as 
described for PCR arrays.  1 µg RNA was reverse transcribed using Transcriptor First 
Strand cDNA Synthesis Kit (Roche) and oligo (dT)18 primer.  PCR was carried out on 
Roche Lightcycler 480: 10 min 95° C followed by 45 cycles of 95° C for 10 s, 55° C for 
30 s, 72° C for 6 s.  Amplification was detected by SYBR green (KAPA) and single PCR 
products were confirmed by melt curve analysis.  Fold regulation was calculated by 
ΔΔCP method with normalization to RPL13A housekeeping gene.  The following gene-
specific primer sets were used:     
 
IL-6 Forward:  GAC AGC CACTCA CCT CTT CA 
IL-6 Reverse:  AGT GCCTCT TTG CTG CTT TC   
 
SST Forward:  TCT GAA CCC AAC CAG AAG GAG AAT 
SST Reverse:  GCT CAA GCC TCA TTT CAT CCT GCT  
 
 
ELISA 
 
IL-6 in cell culture medium was measured by sandwich ELISA according to 
manufacture’s instructions (IL-6: eBioscience or BD bioscience, SST: Phoenix).  ELISA 
were read on Synergy HT (Biotek) plate reader. 
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IL-6 Promoter Activity Assay 
 
BSMC were plated 30,000 cells per well in 12-well plates.  18-24 h after plating, 
each well was transfected with 1.8 µg plasmid expressing the human IL-6 promoter 
driving firefly luciferase expression.  Cells were co-transfected with 0.4 µg Renilla 
luciferase intended as an internal control constitutively expressed via the thymidine 
kinase promoter.  However, Fsk treatment affected Renilla luciferase expression, so it 
could not be used for normalization in our studies.  All transfections used the CalPhos 
(Clontech) calcium phosphate kit.  Experiments were begun 48 h post-transfection.  
Following treatment with the indicated drugs for 6 h, cells were scraped in 250 µL 
passive lysis buffer and assayed using the Dual Luciferase Reporter Assay System 
(Promega).  Luminescence was measured with a TD-20/20 luminometer (Turner 
Designs).   
 
 
cAMP Assay 
 
Cells were washed three times with serum- and NaHCO3-free Dulbecco's 
Modified Eagle's medium (DMEM) supplemented with 20 mM HEPES, pH 7.4 
(DMEH). After equilibration at 37 ̊C for 30 min, cells were pretreated with 0.2 mM 
IBMX, a broadly specific PDE inhibitor, then exposed to the indicated drug for 10 min.  
Assay medium was aspirated and 150 μL 5% trichloroacetic acid was added to each well 
to terminate the reaction. cAMP content of the lysis buffer extract was quantified using 
the cAMP EIA Kit (Cayman Chemical) using the manufacturer’s acetylation protocol.  
 
 
Data Analysis and Statistics 
 
Data are presented as the mean ± SEM. Statistical comparisons (t tests and one-
way analysis of variance) were performed and graphics were generated using GraphPad 
Prism 5.0f (GraphPad Software Inc., San Diego, CA). 
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CHAPTER 3.    cAMP-MEDIATED GENE REGULATION IS AC 
ISOFORM-DEPENDENT 
 
 
Introduction 
 
BSMC predominantly express AC isoforms 2, 4 and 6 (Bogard et al. 2011). These 
isoforms differ in their regulation (Table 1-1), localization, and interactions with other 
proteins, giving them the potential to signal in unique ways and control distinct responses 
even when expressed in the same cell.  AC isoforms are divided into 4 groups based on 
their structure and features of their regulation.  Group I consists of AC1, AC3, and AC8; 
group II: AC2, AC4, and AC7; group III: AC5 and AC6; and group IV: AC9 (Patel et al. 
2001).  In BSMC, AC6 is localized to lipid rafts where it colocalizes with β2AR (Bogard 
et al. 2011).  AC2 and AC4 are excluded from lipid rafts and colocalize with 
prostaglandin E2  receptors (EP2R) (Bogard et al. 2011).  BSMC express several AKAP 
scaffolding molecules, which arrange signaling complexes and interact with AC in an 
isoform-specific manner (Dessauer 2009; Horvat et al. 2012).  AC2 is known to interact 
with multiple AKAP including mAKAP, Yotiao/AKAP9, and AKAP79/150, which bring 
cAMP produced by AC2 in close proximity to prearranged signaling cascades and 
regulators such as PDE and phosphatases (Piggott et al. 2008; Kapiloff et al. 2009; Scott 
et al. 2013).  AC6 is also associated with AKAP, and it has been shown to interact 
directly with AKAP79 (Efendiev et al. 2010).  
 
AC is the limiting factor in determining the maximal effect following Gαs-coupled 
receptor stimulation (Ostrom et al. 2000b; Gao et al. 1998).  Overexpression of AC 
enhances responses to Gαs-coupled receptor stimulation.  In BSMC we use adenoviral 
overexpression of AC and subtractive analysis to study responses mediated by individual 
isoforms.  BSMC have low transfection efficiency, but adenoviral infection results in a 
high percentage of cells overexpressing protein of interest.  β galactosidase assays 
confirmed over 90% of BSMC are positive for lacZ when infected with lacZ encoding 
adenovirus (Bogard et al. 2011). Knockdown of AC isoforms with siRNA would be an 
alternative approach and is appealing, since the individual isoforms that are left would be 
expressed at endogenous levels.  However, a high degree of knockdown would be 
unlikely due to the long half-life of AC, and it would be particularly difficult in poorly 
transfected cells such as BSMC.  We also used newly characterized AC inhibitors 
selective for particular AC isoforms.  A number of pharmacological inhibitors have been 
used to study AC isoforms, but questions were raised about claims of presumed isoform 
selectivity of these inhibitors.  Two recent studies sought to better describe the effect of 
inhibitors on particular AC isoforms.  Though previously described as an AC5-selective 
inhibitor, SQ22,536 inhibits AC5 and AC6 equally.  The IC50 for SQ22,536 at AC6 is 
5.8 µM, and its IC50 at AC2 is 210 µM (Brand et al. 2013).  Conley et. al. screened over 
700 compounds and identified SKF-83566 as an AC2-selective inhibitor (2013).  We 
hypothesized that differences among AC isoforms and compartmentation of cAMP 
signaling allows AC isoform-specific regulation of gene expression.  We used PCR 
arrays and isoform-specific AC inhibitors to show that some cAMP-responsive genes are 
differentially regulated by individual AC isoforms in BSMC. 
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Results 
 
 
A number of genes are differentially regulated by overexpression and activation of 
specific AC isoforms 
 
We tested the hypothesis that cAMP produced by a particular AC isoform has 
unique effects on gene expression by using PCR arrays to examine 84 cAMP- and Ca2+- 
sensitive genes.  PCR arrays allow simultaneous analysis of multiple genes by utilizing 
specially designed primer pairs such that all have been optimized for amplification of 
their specific target under identical conditions.  Control or AC overexpressing cells were 
treated with 1 µM Fsk for 24 h before RNA was isolated and reverse transcribed.  The 
resulting cDNA was diluted in SYBR green master mix and distributed among the wells 
of the PCR array, each with a primer pair specific to a particular gene or control. 
 
Expression of each gene in AC overexpressing cells treated with Fsk was 
compared to Fsk-treated control cells.  Control cells were transfected with empty 
pEGFP-n1 vector or treated with an adenovirus expressing the lacZ gene.  Fold change 
was calculated by the ΔΔCP method with respect to lacZ Fsk-treated cells.  A change in 
expression of 3-fold or greater was the cutoff we used to highlight genes that were 
upregulated or downregulated upon AC overexpression.  For genes that displayed a 
substantial change with AC overexpression, we examined whether there were differences 
in gene regulation based on overexpression of individual isoforms.  Changes in RNA 
levels smaller than 3-fold might be physiologically significant, but we choose to focus on 
the larger responses in this study.  Although Fsk treatment altered the expression of many 
of the genes compared to vehicle in control BSMC, we focused on genes that were 
differentially regulated with overexpression of specific AC isoforms.  
 
 
BSMC 
 
Adenoviral vectors were used to overexpress AC2, AC3, AC6, or lacZ (control) 
in BSMC.  AC2 and AC6 are natively expressed in distinct membrane microdomains in 
BSMC and AC3 was included as a representative group I isoform.  AC overexpression 
altered the Fsk-induced expression of 13 of the cAMP-sensitive genes tested by at least 
3-fold in BSMC (Table A-1).  The genes of greatest interest were those that were 
differentially regulated when different AC were overexpressed.  Overexpression of AC3 
did not produce a 3-fold or greater change in any of the genes tested; however, AC2 and 
AC6 had distinct effects on expression of a number of genes (Figure 3-1).  AC2 and AC6 
overexpression could enhance or attenuate Fsk induction and had differing effects 
depending on the AC isoform and the gene.  A subset of genes was chosen to 
demonstrate the diversity of responses with different AC isoforms overexpressed, and 
results are graphed as fold change with respect to lacZ to illustrate the effect of the 
individual AC being overexpressed (Figure 3-1).  Fsk-mediated expression of 
amphiregulin (AREG) was augmented to a greater extent by AC6 overexpression than 
AC2.  AC2 overexpression reduced the expression of secretogranin II (SCG2), while  
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Figure 3-1. Fsk-induced gene regulation in AC overexpressing BSMC compared 
to control BSMC 
RT2 q PCR arrays (SA Biosciences) were used to measure mRNA levels following 24 h 
treatment with 1μM Fsk.  mRNA levels of AC overexpressing, Fsk-treated cells are 
expressed as fold change with respect to lacZ (control), Fsk- treated cells.  Amphiregulin 
(AREG), Secretogranin II (SCG2), Cyclin D1 (CCND1), Interleukin 6 (IL-6), 
Somatostatin (SST).   Dashed line represents no change with respect to lacZ.  Data are 
presented as fold change with respect to lacZ, mean ± SEM, n=3. 
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AC6 overexpression reduced the expression of cyclin D1 (CCND1).  Fsk-mediated 
expression of Interleukin 6 (IL-6) was enhanced only by AC2 overexpression and  
somatostatin (SST) was enhanced only by AC6 overexpression (Figure 3-1).  IL-6 and 
SST were targets for further study due to their clear AC isoform-dependent patterns of 
gene regulation in BSMC. 
 
 
HEK-293 
 
After finding that gene expression can be regulated differently by AC isoforms in 
BSMC, HEK-293 cells were tested to determine whether this is a generalizable 
phenomenon or unique to BSMC.  HEK-293 cells were transfected with AC2, AC6, or 
pEGFP-n1 (control) vectors then exposed to 1 µM Fsk for 24 h.  As in BSMC, expression 
of some cAMP-sensitive genes was altered by AC overexpression.  Different genes were 
impacted by AC overexpression in the different cell types, and in HEK-293 the effects of 
AC overexpression tended to be smaller (Figure 3-2 and Table A-2).  As in BSMC, AC 
overexpression could enhance or reduce Fsk-induced RNA expression in HEK-293 in an 
isoform-specific manner.  Calponin 1 (CNN1) RNA levels were reduced by AC6 
overexpression, but not AC2.  Gastric inhibitory polypeptide receptor (GIPR) expression 
was enhanced only by AC2 overexpression and tumor necrosis factor (TNF) expression 
was enhanced only by AC6 overexpression (Figure 3-2).  
 
 
Fsk-induced SST mRNA expression and protein production is specifically regulated 
by AC6 in BSMC 
 
In the PCR array, overexpression of AC6 enhanced Fsk-induced SST mRNA 
expression by 9.73 fold in BSMC, while AC2 overexpression had no effect on SST 
expression (Figure 3-1).  24 h was a reasonable starting point for measuring Fsk-
stimulated expression of many different genes in the array, but once SST and IL-6 
emerged as genes of interest with specific regulation by different AC isoforms, time 
course studies were completed to determine the optimal treatment time for further 
experiments.  SST mRNA peaked at 3 h in response to 1 µM Fsk (Figure 3-3).   
  
One µM Fsk resulted in a particularly robust induction of the SST gene, so 
0.3 µM Fsk treatments were used in subsequent studies to avoid a saturation of the 
response that might prevent noticeable enhancement by AC overexpression.  Exposure to 
0.3 µM Fsk for 3 h caused a 26.68-fold increase in SST mRNA compared to vehicle in 
control cells (Figure 3-4).  With overexpression of AC6, the effect of Fsk was enhanced 
and SST mRNA was 67.48-fold above vehicle.  AC2 overexpression did not alter SST 
when compared to control cells with native AC expression (25.74-fold over vehicle).   
 
To determine if the increased SST mRNA in AC6 overexpressing cells results in 
increased protein, we used ELISA to measure SST in cell culture medium.  As early as 
3 h the effect of AC6 overexpression was observed as increased SST protein 
(Figure 3-5).  AC6 overexpression more than doubled Fsk-induced SST production by 
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Figure 3-2. Fsk-induced gene regulation in AC overexpressing HEK-293 
compared to control HEK-293  
RT2 q PCR arrays (SA Biosciences) were used to measure mRNA levels following 24 h 
treatment with 1μM Fsk.   mRNA levels of AC overexpressing, Fsk-treated cells are 
expressed as fold change with respect to empty pEGFP-n1 vector (control), Fsk- treated.   
Calponin 1 (CNN1), Gastric inhibitory polypeptide receptor (GIPR), Tumor necrosis 
factor (TNF).  Dashed line represents no change with respect to empty vector.  Data are 
presented as fold change with respect to empty vector, n=1.  
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Figure 3-3. Time course of Fsk-induced SST mRNA expression 
SST mRNA expression was measured by qRT-PCR in AC6 overexpressing cells exposed 
to 1 µM Fsk for the indicated time.  SST mRNA levels are expressed with respect to lacZ 
basal, n=1.   
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Figure 3-4. Fsk-induced SST mRNA expression in AC overexpressing BSMC 
qRT-PCR was used to determine SST RNA expression in BSMC treated with 0.3 µM Fsk 
for 3 h.  Data are presented as fold change with respect to lacZ basal, mean ± SEM, n=3. 
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Figure 3-5. Fsk-induced SST protein production in AC overexpressing BSMC 
ELISA were used to measure SST secreted into culture medium by BSMC treated with 
0.3 µM Fsk for 3 h.  Data are presented as pg/mL SST.  n=1-2.  
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BSMC in 3 h, from 50.29 pg/mL to 111.69 pg/mL. AC2 overexpression did not enhance 
SST production (Figure 3-5).    
 
 
Fsk-induced IL-6 mRNA expression and protein production is specifically regulated 
by AC2 in BSMC 
 
AC2 overexpression clearly enhanced Fsk induction of IL-6 in the PCR array, but 
AC6 overexpression had no effect.  In control BSMC, time course studies showed that 
IL-6 mRNA peaked at 1 h in response to 1 µM Fsk (Figure 3-6).  At 1 h, 1 µM Fsk 
increased IL-6 mRNA in control cells by 8.16-fold (Figure 3-7A).  The enhancement of 
IL-6 mRNA levels by AC2 overexpression was less pronounced at 1 h (Figure 3-7A) 
than 24 h (Figure 3-1), but since Fsk-stimulated IL-6 mRNA levels peaked at 1 h, this 
time point was used in all subsequent studies.  AC2 overexpression resulted in a near 
doubling of IL-6 mRNA compared to control cells also exposed to 1 µM Fsk for 1 h.  
AC6 did not alter Fsk-induced IL-6 expression compared to control cells (Figure 3-7A).   
 
To determine if the increased IL-6 mRNA in AC2 overexpressing cells translated 
to increased protein, IL-6 protein secreted into culture medium was measured by ELISA.  
1 µM Fsk resulted in IL-6 protein production that increased sharply between 10 and 24 h 
then continued to accumulate over time (Figure 3-8).  24 h was chosen as the time point 
for all other studies measuring IL-6 protein.  Unlike mRNA, where Fsk induced a 
8.16-fold increase over vehicle in control cells, IL-6 protein levels were only slightly 
increased by Fsk (Figure 3-7B).  In control cells 24 h Fsk treatment increased IL-6 by 
11% (from 594 pg/mL in vehicle-treated cells to 668 pg/mL in Fsk-treated).  AC2 
overexpression enhanced Fsk-induced IL-6 protein production to 942 pg/mL.  
Overexpression of AC6 did not increase IL-6 over control cells, and in fact IL-6 was 
slightly lower in AC6 overexpressing cells (652 pg/mL) compared to control BSMC with 
native AC expression (Figure 3-7B).   
 
Recent studies characterizing AC inhibitors have identified SKF-83566 as AC2-
selective and SQ22,536 as AC5/6-selective (Conley et al. 2013; Brand et al. 2013).  We 
used these inhibitors as another approach to investigate the AC2-specific induction of 
IL-6.  We pretreated BSMC with each of these inhibitors prior to 1 µM Fsk treatment.  
Pretreatment with 30 µM SKF-83566 for 20 min reduced Fsk induction of IL-6 mRNA 
by 48.21% (Figure 3-9). The effect of SQ22,536 pretreatment on IL-6 promoter activity 
was measured by luciferase assay.  SQ22,536 did not significantly reduce Fsk-induced 
IL-6 promoter activity when the inhibitor was added at 1, 3, or 10 µM for 30 min prior to 
Fsk treatment (Figure 3-10).  
 
 
IL-6 basal expression and induction by Fsk differ in BSMC from an asthmatic 
donor 
 
IL-6 levels in BALF and serum are increased in patients with asthma, and BSMC 
could be one contributor to raised IL-6 levels (Rincon and Irvin 2012).  We   
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Figure 3-6. Time course of Fsk-induced IL-6 mRNA expression 
qRT-PCR was used to measure IL-6 mRNA expression in control BSMC exposed to 
1 µM Fsk for the indicated time.  Data are expressed as the inverse of the CP, mean ± 
SEM, n=2-3.  
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Figure 3-7. Fsk-induced IL-6 mRNA expression and protein production in AC 
overexpressing BSMC 
(A) qRT-PCR was used to detect IL-6 mRNA levels in BSMC exposed to 1 µM  Fsk for 
1 h.  mRNA levels of Fsk-treated cells are expressed as fold change with respect to lacZ 
basal, mean ± SEM, n=3.  Dashed line represents no change with respect to lacZ basal. 
* indicates p<.05 compared to lacZ.  (B) ELISA were used to measure IL-6 secreted into 
culture medium by BSMC treated with 1 µM Fsk for 24 h.   Data are presented % change 
with respect to lacZ basal, mean ± SEM, n=3.  * indicates p<.05 compared to lacZ basal. 
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Figure 3-8. Time course of Fsk-stimulated IL-6 protein production 
ELISA were used to measure IL-6 protein in cell culture medium following exposure to 
1 µM Fsk for the indicated amount of time.  Mean  ± SEM, n=1-2.  
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Figure 3-9. Inhibition of Fsk-induced IL-6 expression with AC2-selective 
inhibitor 
qRT-PCR was used to determine IL-6 mRNA levels in BSMC pretreated with 30 µM 
SKF-83566 or vehicle for 20 min prior to 1 h, 1 µM Fsk treatment.  mRNA levels are 
expressed relative to vehicle treated, mean ± SEM, n=4.  Dashed line represents no 
change with respect to vehicle.  * indicates p<.05 compared to Fsk alone. 
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Figure 3-10. Inhibition of Fsk-induced IL-6 promoter activation with AC6-
selective inhibitor 
Luciferase assays were used to determine IL-6 promoter activation in BSMC pretreated 
with the indicated concentration of SQ22,536 or vehicle for 30 min prior to 6 h, 1µM Fsk 
treatment. Luminescence is expressed relative to vehicle treated, mean ± SEM, n=4. 
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wondered if cAMP-mediated IL-6 induction differed in BSMC from an asthmatic donor 
compared to a non-asthmatic donor. Cells from different donors were cultured in 
identical growth medium with the intent to uncover any intrinsic changes in IL-6 
induction pathways in asthmatic BSMC.  BSMC from an asthmatic donor had basal 
levels of IL-6 mRNA that were 3-times higher than BSMC from a non-asthmatic donor 
(Figure 3-11).  When BSMC from the asthmatic donor were treated with 1 µM Fsk, there 
was no increase in IL-6 mRNA compared to those cells untreated.  In non-asthmatic 
BSMC treated at the same time, Fsk treatment caused a 2.6-fold increase in IL-6 mRNA 
levels. IL-6 expression is increased in asthmatic BSMC at rest, and AC activation by Fsk 
is unable to further stimulate IL-6 transcription as it does in healthy BSMC.  
 
 
Discussion 
 
A number of genes that are differentially regulated by individual AC isoforms in 
BSMC and HEK-293 were identified by PCR array (Figures 3-1 and 3-2).  In BSMC 
IL-6 is selectively regulated by AC2 and SST is selectively regulated by AC6. AC 
isoform-specific enhancement of the induction of these genes results in increased protein 
production (Figures 3-5 and 3-7B). Basal expression of IL-6 is increased in asthmatic 
BSMC, and induction by Fsk is impaired (Figure 3-11).    
 
 
Cell-type differences 
 
BSMC are highly differentiated cells with unique physiological roles. To confirm 
that AC isoform-specific regulation of gene expression is a generalizable phenomenon, 
we also tested the less well differentiated HEK-293 cells.  Both cell types have cAMP 
regulated genes and genes that are differentially regulated when specific AC isoforms are 
overexpressed (Figures 3-1 and 3-2).  Interestingly, the AC isoforms that are 
predominately expressed in these cell types are similar, but the degree of 
compartmentation differs greatly.  It is not surprising that cAMP stimulates different 
genes in cell types with distinct physiological roles.  
 
One methodological difference in these studies is the mode of AC overexpression.  
BSMC have poor transfection efficiency, whether using lipofectamine or calcium 
phosphate transfection methods.  Therefore adenoviral vectors were used to overexpress 
proteins of interest in BSMC.  β galactosidase staining indicates lacZ expression in 
greater than 90% of BSMC following adenoviral mediated gene transfer (Bogard et al. 
2011).  HEK-293 efficiently take up plasmids when transfected, but adenoviral 
overexpression cannot be used in HEK-293. They cannot be infected with adenovirus to 
overexpress AC because they are packaging cells that contain the E1 and E3 adenoviral 
genes, which allow adenoviral replication and lysing of the cells.  
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Figure 3-11. Fsk induction of IL-6 in normal and asthmatic BSMC 
qRT-PCR was used to detect mRNA levels in BSMC exposed to 1 µM  Fsk for 1 h.  
mRNA levels are expressed as fold change with respect to normal basal, mean ± SEM, 
n=3. 
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IL-6 and asthma pathogenesis 
 
The finding that AC2 specifically regulates expression of the pro-inflammatory 
cytokine IL-6 in BSMC is of particular interest due to its role in the pathogenesis of 
asthma.  IL-6 is increased in the serum and BALF of asthmatic patients and is inversely 
correlated with lung function (Neveu et al. ; Morjaria et al. 2011).  IL-6 is more than just 
a marker of inflammation in asthma.  It can be secreted by structural cells independent of 
inflammation and plays a role in the development and worsening of pathological changes 
associated with asthma (Rincon and Irvin 2012).  IL-6 has many effects in the airway.  
The main targets of IL-6 are immune cells, but soluble IL-6 receptors and trans-signaling 
allow IL-6 to mediate responses in most cell-types (Rose-John et al. 2006).  IL-6 
encourages the differentiation of CD4+ T cells to Th2 cells and inhibits maturation of Th1 
cells (Diehl and Rincon 2002).  This bias toward Th2 is likely involved in many 
pathological features of asthma including inflammation, mucus secretion, and airway 
hyper-responsiveness (Georas et al. 2005).  IL-6 increases airway resistance and causes 
smooth muscle hypertrophy and hyperplasia in rodents (De et al. 1995; Rubini 2010).  
IL-6 is obviously important in asthma pathology, and treatment with βAR agonists may 
be increasing IL-6 production through AC2-mediated signaling.  A better understanding 
of the cAMP signaling compartments associated with regulating IL-6 expression could 
allow for more precisely targeted asthma therapies in the future.  
 
We found that IL-6 expression was increased in BSMC from an asthmatic donor 
compared to cells from a healthy donor under basal conditions.  BSMC from the 
asthmatic donor did not respond to Fsk with increased IL-6 expression as the normal 
BSMC did.  The lack of Fsk response could be explained by the high basal IL-6 
expression.  If the pathways responsible for induction of IL-6 are constitutively active in 
asthmatic BSMC, Fsk may not have a further effect.  Figure 3-11 represents data 
gathered from multiple treatments of cells isolated from 2 donors.  The data here do not 
allow us to draw conclusions about difference between asthmatic and non-asthmatic 
BSMC, because they are only from a single asthmatic and a single non-asthmatic donor.  
IL-6 induction by cAMP signaling in BSMC from asthmatic and non-asthmatic donors 
should be repeated with cells from additional donors before conclusions can be made.    
 
 
AC isoform differences 
 
We show that genes can be regulated differently by individual AC isoforms.  In 
BSMC AC2, AC4, and AC6 are endogenously expressed, and we have shown that AC2 
and AC6 have distinct effects on expression of various genes when they are 
overexpressed and activated in BSMC.  AC3 was included in our study to represent 
group I AC, and it was not associated with changes in Fsk-mediated gene regulation 
compared to control BSMC.  With IL-6 found to be specifically regulated by AC2-
derived cAMP, the rest of this project focused on uncovering the signaling pathways 
involved to determine how AC2- but not AC6-derived cAMP is associated with induction 
of IL-6.
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CHAPTER 4.    RECEPTOR MEDIATED IL-6 INDUCTION IN BSMC 
 
 
Introduction 
 
There are over 800 genes encoding GPCR in the human genome (Fredriksson et 
al. 2003).  Patterns of receptor expression are dependent on cell type, and most cells 
express many different GPCR (Hakak et al. 2003).  Activities of more than 20 GPCR 
have been described in BSMC, with at least 5 different receptors coupling to Gαs  
(Billington and Penn 2003).  Since receptors contribute to compartmentation due to 
differences in their associations with AC isoforms, we hypothesized that only a subset of 
receptors in BSMC would be linked to induction of IL-6.  Many different receptor types 
have been implicated in IL-6 induction in various cell types. Among the Gαs-coupled 
receptors that have been linked to IL-6 induction in other cells are β2AR, β3AR, EP2R, 
tachykinin, CGRP, adenosine A2B, and purinergic receptors (Chen et al. 2012; 
Tchivileva et al. 2009; Fiebich et al. 2000; Millet and Vignery 1997; Wang et al. 2010; 
Zhong et al. 2005; Inoue et al. 2007).  If expressed in the right signaling compartment, 
these Gαs-coupled receptors have the potential to induce IL-6 in BSMC.   
  
One way that AC isoforms differentially regulate cellular responses is through 
isoform-specific associations with receptors (Ostrom et al. 2000c).  Colocalization in 
specialized membrane microdomains can promote specific AC-receptor interactions.  
Lipid rafts are specialized domains within the plasma membrane with high levels of 
cholesterol and sphingolipids.  Caveolae represent a subset of lipid rafts distinguishable 
by their flask-like shape and expression of caveolin proteins.  Interactions with 
membrane lipids or proteins allow enrichment of certain signaling molecules in lipid rafts 
while others are excluded (Ostrom and Insel 2004).  The content of caveolae is dynamic 
and translocation can alter the regulation and responses of signaling molecules (Ostrom et 
al. 2001; Rybin et al. 2000). There are likely several mechanisms acting to target specific 
proteins to lipid rafts and caveolae, including protein-lipid interactions, protein-protein 
interactions and post-translational modifications (Moffett et al. 2000; Resh 2006; Hnasko 
and Lisanti 2003).  Cell-specific differences in localization of receptors and AC have 
been observed for both native and overexpressed protein, providing an additional 
mechanism for cell-specific cAMP-mediated responses (Ostrom et al. 2000c; Ostrom et 
al. 2002).  Colocalization in lipid rafts facilitates specific receptor-AC associations and 
interactions with downstream effectors and is likely responsible for some receptor-
specific and AC isoform-specific cellular responses (Pike 2003).  
 
Particular GPCR-AC associations have been described in a number of different 
cells, including BSMC.  βAR and AC6 are colocalized and interact in caveolae in 
neonatal cardiac myocytes, and a number of other receptors do not have access to AC6 in 
this compartment (Ostrom et al. 2000c).  In BSMC AC6 and β2AR colocalize in 
caveolae, while AC2 and AC4 are excluded from them.  EP2R colocalize and interact 
with AC2/AC4 outside of lipid rafts and cannot stimulate AC6 (Bogard et al. 2011).  
Specific GPCR-AC coupling can also occur through direct protein-protein interactions or 
AKAP-organized complexes (Lavine et al. 2002; Dessauer 2009).  Due to specific 
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localization and interactions of GPCR with AC and downstream effectors, we 
hypothesized that not all Gαs coupled receptors are associated with AC2 and tied to 
induction of IL-6 expression. We examined expression of GPCR in BSMC and used 
specific agonists to activate GPCR to determine which receptors stimulate IL-6 
production.    
 
 
Results 
 
 
Receptor-mediated induction of IL-6 is enhanced specifically by AC2 
 
After finding that direct activation of AC with Fsk resulted in an induction of IL-6 
that was enhanced specifically by AC2 overexpression and not other AC isoforms, we 
wanted to determine if AC2 specificity persists when IL-6 is induced by activation of 
Gαs-coupled receptors.  We hypothesized that colocalization of receptors, AC, and 
downstream effectors create distinct cAMP signaling compartments in BSMC.  We have 
previously shown that AC2 and EP2R are excluded from lipid rafts in BSMC, and that 
β2AR are predominately localized to lipid rafts where they colocalize with AC6 (Bogard 
et al. 2011).  These receptors have also been shown to induce IL-6 expression in other 
cell-types (Chen et al. 2012; Fiebich et al. 2001).  Thus, we stimulated β2AR with 
isoproterenol (Iso) or EP2R with butaprost (Buta) for 24 h and measured IL-6 mRNA by 
qRT-PCR and IL-6 secreted into culture supernatant by ELISA.  
 
Iso and Buta were both able to induce IL-6 expression in BSMC.  In control and 
AC overexpressing cells these agonists caused a significant increase in IL-6 mRNA 
(Figure 4-1).  AC2 overexpression significantly enhanced IL-6 mRNA production in Iso 
treated cells compared to cells expressing only native levels of AC.  Since the effect of 
Buta on IL-6 induction was highly variable, AC2’s effect did not reach statistical 
significance.  AC6 overexpression did not change RNA levels compared to control cells 
in response to any of the agonists tested. 
 
Treatment with Iso or Buta also increased IL-6 protein in an AC2-specific manner 
(Figure 4-2).  Unlike mRNA, these agonists did not significantly increase IL-6 protein 
compared to vehicle in control cells.  Only in AC2 overexpressing cells did Iso and Buta 
treatments result in significant increases in IL-6 production.  AC2 overexpression 
enhanced IL-6 protein production in response to Iso compared to control cells.  As with 
mRNA studies, variability in the response to Buta prevented a statistically significant 
enhancement in AC2 overexpressing cells. AC6 overexpression did not alter IL-6 protein 
levels compared to control cells with endogenous AC expression in any of the conditions 
tested. 
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Figure 4-1. IL-6 mRNA expression in response to GPCR agonists 
qRT-PCR was used to determine IL-6 mRNA levels in BSMC overexpressing lacZ, AC2 
or AC6 treated with 1 µM of the indicated drug for 1 h.  mRNA levels are expressed 
relative to lacZ basal, mean ± SEM, n=6.  * indicates p<.05 compared to basal in lacZ, # 
indicates p<.05 in AC overexpressing cells compared to same treatment in control cells.  
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Figure 4-2. IL-6 protein production in response to GPCR agonists 
ELISA were used to determine IL-6 protein levels in culture medium from BSMC 
overexpressing lacZ, AC2 or AC6 treated with 1 µM of the indicated drug for 24 h.  
Dashed line indicates no change with respect to lacZ basal.  IL-6 protein is expressed 
relative to lacZ basal, mean ± SEM, n=3.  * indicates p<.05 compared to lacZ basal, # 
indicates p<.05 in AC overexpressing cells compared to same treatment in control cells.  
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BSMC express several GPCR 
 
GPCR expression is cell-type dependent and most cells express many different 
receptors.  The full complement of receptors expressed in BSMC has not been described 
previously.  To better understand how AC2 specifically enhances IL-6, we wanted to 
know whether all Gαs-coupled GPCR, or only a subset, are able to stimulate IL-6 gene 
expression.  To determine which GPCR are expressed in BSMC, we used PCR arrays to 
probe for mRNA of 370 receptors (Table A-3).  Following amplification, SYBR green 
melt curves were analyzed, and genes with more than one peak were excluded due to the 
ambiguity associated with multiple products.  It is important to note that the PCR array 
data are qualitative in this context.  Since cDNA for each receptor was amplified with 
different primers resulting in products of varying lengths, receptors with lower CP values 
are not necessarily expressed at higher levels.  The PCR array served as a starting point to 
discover all the GPCR expressed by BSMC, but ultimately other approaches must be 
used to confirm functional receptor expression.  mRNA was detected (CP <35) for 227 of 
the receptors tested, while mRNA was not detected (CP >35) for 81 receptors 
(Table  A-3). 
 
The PCR array detected mRNA for β2AR, with an average CP of 29.90.  
Amplification by EP2R primers was also apparent (CP: 26.59), but since there were 
multiple peaks on the melt curve the data were not conclusive, and this receptor was not 
included in Table A-3.  EP2R expression in BSMC has been confirmed by other methods.  
EP2R immunoblots and the ability of Buta, an EP2R-selective agonist, to increase cAMP 
and IL-6 (Figure 4-1) indicate that this receptor is expressed in BSMC (Bogard et al. 
2011).  The CP of other receptors potentially associated with IL-6 induction are listed in 
Table 4-1 with their predominant G-protein associations and the agonists used to 
investigate their activity in BSMC.  
 
 
Not all receptors are associated with induction of IL-6 
 
We chose a subset of the receptors with readily detectible mRNA and measured 
cAMP and IL-6 production following stimulation with specific agonists (Table 4-1).  
IL-6 protein in culture medium increased compared to vehicle following 24 h treatment 
with a purinergic receptor agonist, ATPƔS, or adenosine receptor agonist, 5'-N-
ethylcarboxamidoadenosine (NECA, Figure 4-3A).  Arginine vasopressin (AVP), BRL 
37344 (β3AR-selective agonist), α-calcitonin gene related peptide (α-CGRP), glucagon, 
prostaglandin D2 (PGD2), and substance P did not significantly increase IL-6 secretion 
compared to vehicle (Figure 4-3A).   
 
We also tested these agonists for their ability to stimulate cAMP production in 
BSMC.  Cells were treated with the same GPCR-selective agonists for 10 min in the 
presence of a broad-spectrum PDE inhibitor (0.2 mM IBMX). ATPƔS and NECA, 
agonists that increased IL-6 secretion, did not significantly increase global cAMP levels 
(Figure 4-3B).  The cAMP response to NECA may be blunted by antagonism of  
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Table 4-1. GPCR agonists and their targets in BSMC 
 
Agonist 
 
Receptor Activity Affinity G-protein  CP 
ATPƔS  P2Y12  Full 
agonist 
 
5.5a Gi/Go 40  
ATPƔS P2Y11  Full  
agonist 
 
4.9 – 5.5b 1˚:  Gq/G11 
2˚: Gs 
29.13 
ATPƔS P2Y1  Partial 
agonist 
  
7.4c 1˚:  Gq/G11 
2˚:  Gi/Go 
34.49 
ATPƔS P2Y13  Full  
Agonist 
 
5.5c Gi/Go 33.92 
AVP  Vasopressin 
V1B 
Full 
agonist 
  
9.0 – 9.5 a Gq 31.00 
AVP Vasopressin 
V1A 
Full  
agonist 
 
8.5 – 9.3 a Gq/G11 31.63 
AVP Vasopressin V2 Full  
agonist 
 
7.9 – 9.1 a Gs 33.55 
AVP OT Receptor Partial 
agonist 
  
7.3 – 9.3 a Gi/Go 27.42 
 
BRL 
37344  
β3 Adrenergic Full  
agonist 
 
6.4 – 7a 1˚: Gs 
2˚:  Gi/Go 
30.96 
αCGRP AM1 Full   
agonist 
6.0d 
 
1˚: Gs 
2˚: Gi/Go,     
      Gq/G11 
RAMP2
: ND 
CALCR
L: 31.76 
 
αCGRP CGRP Full  
agonist 
9.7 – 10 a 1˚: Gs 
2˚: Gi/Go,     
      Gq/G11 
RAMP1
: ND 
CALCR
L: 31.76 
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Table 4-1. (Continued) 
 
Agonist 
 
Receptor Activity Affinity G-protein  CP 
αCGRP AM2 Full  
agonist   
 
 
 
6.5 – 6.8 a 1˚: Gs 
2˚: Gi/Go,     
      Gq/G11 
RAMP3
: ND 
CALCR
L: 31.76 
αCGRP AMY1 Full  
agonist 
 
 
8.7 – 10.8b  Gs RAMP1
: ND 
CALCR
: 36.08 
 
αCGRP AMY3 Full 
agonist 
 
 
 
7.6 – 9.7b  Gs RAMP3
: ND 
CALCR
: 36.08 
 
αCGRP AMY2 Full 
agonist 
 
 
6.2 – 9.7b Gs RAMP: 
ND 
CALCR
: 36.08 
 
αCGRP CT Full 
agonist 
 
6.2 – 8.4b  1˚: Gs 
2˚:  Gq/G11 
 
36.08 
Glucagon  GLP-1 Full 
agonist 
 
6.9 – 7 a Gs ND 
Glucagon Glucagon Full  
agonist 
 
9.0 b Gs 34.68 
NECA  A3 Full  
agonist 
 
7.5 – 8.4 a Gi 38.79 
NECA A2A Full   
agonist 
 
6.9 – 8.7 a 1˚: Gs 
2˚: Gq/G11 
 
32.47 
NECA A1 Full   
agonist   
 
 
5.3 – 8.2 a 1˚: Gi/Go 
2˚: Gs 
      Gq/G11 
 
32.01 
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Table 4-1. (Continued) 
 
Agonist 
 
Receptor Activity Affinity G-protein  CP 
NECA A2B Full   
agonist 
 
5.7 – 6.9 a 1˚: Gs 
2˚: Gq/G11 
 
27.61 
PGD2  EP4 Full   
agonist 
 
8.7 – 9 a 1˚: Gs 
2˚: Gi/Go 
 
27.71 
PGD2 DP1 Full  
agonist 
 
7.8 – 9.2 a Gs 32.92 
PGD2 DP2 Full 
agonist 
 
7.6 – 8.6 a Gi/Go ND 
PGD2 FP Full  
agonist 
 
7.7 a 1˚: Gq/G11 
2˚: Gs 
28.38 
PGD2 EP2 Full  
agonist 
 
5.0 a Gs 26.59 
PGD2 EP1 Full 
agonist 
 
4.7 a 1˚: Gq/G11  
2˚: Gi/Go 
31.82 
Substance 
P 
NK1 Full 
agonist 
 
8.5 – 10.3 a Gs, 
Gq/G11 
34.49 
Substance 
P 
NK2 Full 
agonist 
 
5.9 – 6.9 a Gs, 
Gq/G11 
32.78 
Substance 
P 
NK3 Full 
agonist 
 
5.0 – 6.0 a Gq/G11 32.75 
 
Notes: Affinities are listed as a, pKi; b, pEC50; c, pIC50; d, pKd.  Some receptors can 
couple to multiple G-proteins.  1˚ represents the primary coupling and 2˚ represents 
secondary coupling.  ND (not determined) indicates genes that were not tested.  
 
Source: Sharman JL, Benson HE, Pawson AJ, Lukito V, Mpamhanga CP, Bombail V, 
Davenport AP, Peters JA, Spedding M, Harmar AJ, Nc I (2013) IUPHAR-DB: updated 
database content and new features. Nucleic Acids Res 41 (Database issue):D1083-1088. 
doi:10.1093/nar/gks960 
 
.     
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Figure 4-3. cAMP and IL-6 protein production in response to Gαs-coupled 
receptor agonists   
BSMC were treated with 1µM Fsk, AVP, CGRP, glucagon, PGD2, substance P; 10 µM 
ATPƔS, BRL 37344, NECA. (A) ELISA were used to measure IL-6 secreted into culture 
media from cells treated with the indicated drug for 24 h.  (B) cAMP was measured by 
EIA in BSMC that were pretreated with 0.2 mM IBMX prior to 10 min agonist. Dashed 
line represents no change with respect to vehicle. Data are presented as the fold response 
over vehicle, mean ± SEM, n=3-4.  * indicates p<.05 compared to vehicle. 
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adenosine receptors by IBMX (Daly et al. 1987).  BRL 37344 and glucagon, agonists that 
did not increase IL-6 production, induced small but non-significant cAMP responses.   
 
 
IL-6 and cAMP levels are not directly correlated  
 
Since levels of IL-6 production did not appear to directly correlate with global 
cAMP levels, we further examined the correlation between cAMP and IL-6 using 
agonists for β2AR and EP2R, receptors whose expression in BSMC and ability to 
stimulate IL-6 in other cell types have been well described (Bogard et al. 2011; 
Raychaudhuri et al. 2010; Chen et al. 2012).  Simultaneous Gαs and Fsk stimulation 
produces a synergistic cAMP response in many cell types that can aid in determining the 
role of this signaling pathway (Insel and Ostrom 2003; Daly et al. 1982; Darfler et al. 
1982; Sutkowski et al. 1994; Ostrom et al. 2000a).  AC2 overexpressing cells were 
treated with 0.1 µM Iso or Buta alone and with concurrent Fsk (0.1 µM) treatment to 
determine if increased cAMP always translates to increased IL-6 production.  Lower 
concentrations of each drug were used in order to observe synergistic effects.  Addition 
of Fsk at the time of Buta stimulation significantly increased cAMP production over 
agonist alone (Figure 4-4A). High variability in Iso-treated cells resulted in a non 
significant effect of Fsk, but addition of Fsk consistently resulted in at least doubling of 
cAMP compared to Iso alone.  Thus, BSMC express a moderate Gαs-Fsk synergistic 
effect.   Using these same conditions, we found no increase in IL-6 production 
(Figure 4-4B).  Simultaneous Gαs and Fsk stimulation increases cAMP substantially, but 
the cAMP increase does not translate to greater IL-6 expression.  cAMP induces IL-6 
expression in BSMC, but the levels of cAMP and IL-6 are not directly correlated.   
 
 
Discussion 
 
Agonists that do not have a significant effect on cAMP levels can induce IL-6 
(Figure 4-3).  Even with PDE inhibition, ATPγS and NECA did not significantly 
increase cAMP production over basal levels. These two agonists can activate GPCR 
coupled to Gαq pathways in addition to Gαs.  Gαq initiates protein kinase C (PKC) and 
mitogen activated protein kinase (MAPK) signaling pathways, which have been shown to 
induce IL-6 expression in other cell types. Additionally, PKC regulates AC activity of 
some isoforms.  PKC can activate AC2, even without stimulation by Gαs or Fsk 
(Jacobowitz and Iyengar 1994).  The ability of ATPγS and NECA to stimulate IL-6 
production without significantly increasing cAMP could be through Gαq activated PKC 
directly activating AC2, or via PKC signaling pathways themselves.   
 
Surprisingly Iso and Buta, agonists targeting receptors that are known to be 
expressed in BSMC and capable of inducing IL-6 expression, did not significantly 
increase protein production in control cells.  With this known, the other agonists would 
have been better tested in AC2 overexpressing cells, or had their ability to induce mRNA 
expression measured instead of protein.  We cannot be certain that the agonists that did 
not show increased protein are not associated with induction of IL-6 gene expression.  
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Figure 4-4. cAMP and IL-6 production in BSMC by GPCR agonists alone or with 
concurrent Fsk treatment  
(A) Cells were treated with 0.1 µM of the indicated drug with or without concurrent 
treatment with 0.1 µM Fsk for 10 min in the presence of 0.2 mM IBMX.  cAMP was 
measured by EIA.  (B) Cells were treated with 0.1 µM of the indicated drug with or 
without concurrent treatment with 0.1 µM Fsk.  IL-6 in culture media was measured by 
ELISA following 24 h drug treatment. Dashed line represents no change with respect to 
basal. Data in both panels are presented as the fold over vehicle, mean ± SEM, n=3. 
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The agonists BRL-37344, substance P, and CGRP stimulate IL-6 production in 
other cells, but they did not increase IL-6 protein production in BSMC (Figure 4-3) 
(Tchivileva et al. 2009; Millet and Vignery 1997; Wang et al. 2010).  There are cell-type 
differences in receptor-mediated induction of IL-6, likely due to differences in receptor 
expression, signaling intermediates and signaling compartments of cells. Gαs-coupled 
receptors β2AR and EP2R are linked to IL-6 induction in BSMC (Figure 4-1).  As 
expected based on Fsk responses AC2 derived-cAMP selectively induces IL-6 in 
response to GPCR stimulation.  Not all Gαs receptors are associated with induction of IL-
6, likely in part due to localization that places them apart from AC2.  In addition to 
colocalization, we found that differences in regulation, particularly AC2 activation by 
PKC, could be involved in some of the GPCR-mediated IL-6 induction downstream of 
AC2.   
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CHAPTER 5.     DOWNSTREAM SIGNALING AND PROMOTER ELEMENTS 
ASSOCIATED WITH cAMP INDUCTION OF IL-6 
 
 
Introduction 
 
cAMP induces IL-6 through various signaling pathways, with differences among 
cell types.  The intermediate signaling molecules linking cAMP to IL-6 induction have 
not been studied in BSMC.  In astrocytes, PGE2 enhances IL-6 expression through 
Gαs-coupled EP4-like receptors and p38 MAPK and PKC pathways (Fiebich et al. 2001).  
In chondrocytes the same stimulus regulates IL-6 expression through PKA and 
phosphatidylinositol 3-kinase (PI3K) pathways (Wang et al. 2010).  IL-6 induction by 
βAR activation in neonatal mouse cardiac fibroblasts is Epac-dependent and involves 
PKCδ and p38 MAPK signaling pathways (Chen et al. 2012).  Since it is clear that 
pathways mediating cAMP induction of IL-6 are cell-type specific, we sought to 
determine which signaling intermediates are required for Fsk-induced IL-6 expression in 
BSMC. 
 
cAMP can regulate gene expression through several different signaling pathways 
and a variety of transcription factors, and by the time the signal has reached the nucleus 
there are many opportunities for crosstalk among various signaling pathways.  The IL-6 
promoter contains C/EBP, CRE, NF-κB, and 2 AP-1 sites (Dendorfer et al. 1994; Akira et 
al. 1990; Tanabe et al. 1988).  Pathways initiated by cAMP have the potential to regulate 
transcription factor and cofactor binding at each of these sites.  The most direct pathway 
linking cAMP to gene induction is through PKA phosphorylation of CREB bound to the 
CRE site (Gonzalez and Montminy 1989).  CREB is bound to chromatin under 
unstimulated conditions, but PKA phosphorylation at Ser 133 leads to binding of CREB 
binding protein (CBP) and recruitment of transcription initiation complexes (Montminy 
1997).  PKA is not the only kinase that phosphorylates CREB at Ser 133, so other 
pathways can also regulate transcription initiation at CRE (Shaywitz and Greenberg 
1999).  AP-1 sites have a consensus sequence that is closely related to the CRE sequence, 
and CREB can also regulate transcription at these sites (Lee et al. 1987; Lamph et al. 
1990).  Transcription at AP-1 is also initiated by Fos-Jun dimers, which are activated by 
MAPK signaling cascades (Karin 1996).  
 
NFκB is involved in induction of many inflammatory genes.  It is sequestered in 
the cytosol by IκB and translocates to the nucleus following phosphorylation of IκB by Iκ 
kinase (IκK).  IκK can be activated by any of the pathways that have been implicated in 
IL-6 induction in other cell types (Hayden and Ghosh 2008).   The transcription factor 
C/EBP is also known as NF-IL-6 (Akira et al. 1990).  Most cells express multiple C/EBP 
isoforms with varying activity.  cAMP induces C/EBP translocation to the nucleus (Metz 
and Ziff 1991).  Interestingly, asthmatic ASM do not express C/EBPα, an inhibitory 
isoform (Roth et al. 2004).  The C/EBP site does not appear to be involved in cAMP-
mediated IL-6 expression, but it may play a role in increased proliferation of ASM in 
asthma (Roth et al. 2004).  AC isoform-specific localization and interactions are involved 
in establishing distinct cAMP signaling compartments that regulate precise cellular 
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responses.  We looked downstream of cAMP to uncover the signaling intermediates 
responsible for transduction of the signal from AC2 to the IL-6 promoter.  We used 
selective cAMP agonists and inhibitors of intermediate kinases and found that PKA and 
Epac are activated downstream of AC2 and stimulate IL-6 induction via CRE and AP-1 
promoter elements.   
 
 
Results 
 
 
PKA and Epac signaling induce IL-6 production 
 
To determine what makes AC2-derived cAMP specifically linked to induction of 
IL-6, we examined the downstream signaling pathways that connect cAMP signals to the 
nucleus.  cAMP transduces signals through activation of PKA and Epac.  Using specific 
cAMP analogs we probed for the role of each of these downstream effector molecules in 
regulating IL-6 levels.  Exposure to 1 µM 8CPT-2Me-cAMP or 8-Br-cAMP did not 
significantly increase IL-6 protein secretion over vehicle (Figure 5-1).  The Epac 
selective analog, 8CPT-2Me-cAMP, significantly increased IL-6 protein at 10 µM and 
100 µM, increasing IL-6 by slightly over 50% at both concentrations.  At 10 µM the non-
selective analog, 8-Br-cAMP, produced a similar response to 8CPT-2Me-cAMP.  
However, treatment with 100 µM 8-Br-cAMP led to a substantially larger response than 
the Epac selective analog, with a 4-fold increase in IL-6 protein over vehicle.  The typical 
response to 1 µM Fsk resulted in IL-6 levels greater than any 8CPT-2Me-cAMP 
concentration and comparable to an 8-Br-cAMP concentration between 10 µM and 
100-µM.   
 
To determine if PKA activity is required for induction of IL-6 in response to Fsk, 
we pretreated cells with the PKA inhibitor H-89.  PKA inhibition reduced IL-6 produced 
in response to 1 µM Fsk by 13.4% (Figure 5-2).  When treated with selective cAMP 
analogs, PKA had a greater role in regulating induction of IL-6 when cAMP levels were 
high.  Increasing the Fsk concentration to 10 µM did not result in any greater reduction of 
IL-6 production by H-89 (Figure 5-2).  10 µM Fsk produces maximal cAMP production 
in BSMC, but the intracellular cAMP levels are probably not as high as treatment with 
100 µM 8-Br-cAMP.  Epac and PKA are responsible for cAMP-mediated induction of 
IL-6. PKA produces large increases in IL-6 in response to high cAMP levels, but Epac 
appears to regulate much of the IL-6 expression induced by Fsk treatment.  
 
 
Inhibition of PKC, p38 MAPK, or PI3K does not block Fsk induction of IL-6 
  
We used inhibitors of PKC (GF 109203X), p38 MAP kinase (SB 202190), or 
PI3K (wortmanin) to probe for the role of these signaling pathways, since work in other 
cell types implicates them in Gαs-mediated induction of IL-6 (Fiebich et al. 2001; Wang 
et al. 2010).  BSMC were pretreated for 1 h with 10 µM of each inhibitor, concentrations 
that significantly inhibited IL-6 expression in other cell types (Fiebich et al. 2001; 
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Figure 5-1. IL-6 protein production induced by cAMP analogs 
ELISA were used to measure IL-6 protein in the culture medium of BSMC following 
24 h treatment with the indicated concentration of 8-Br-cAMP or 8CPT-2Me-cAMP. 
Dashed line represents no change with respect to vehicle. Data are presented relative to 
vehicle, mean ± SEM, n=4. * indicates p<.05 compared to vehicle, # indicates p<.05 
compared to 8CPT-2Me-cAMP. 
42
 
Figure 5-2. IL-6 protein production by Fsk in the presence of PKA inhibitor 
ELISA were used to measure IL-6 in culture supernatant of cells pretreated with 3 µM 
H-89 or vehicle prior to 24 h 1 µM Fsk. Dashed line represents no change with respect to 
vehicle. Data are presented relative to vehicle, Mean ± SEM, n=4.  * indicates p<.05 
compared to Fsk alone.  
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Wang et al. 2010).  Following inhibitor pretreatment, cells were exposed to 1 µM Fsk for 
1 h, and IL-6 mRNA expression was measured by qRT-PCR.  None of the inhibitors 
tested had a significant inhibitory effect on Fsk-stimulated IL-6 expression (Figure 5-3). 
In fact, GF 109203X or wortmanin pretreatment tended to increase IL-6 production 
compared to Fsk alone (not significant).  Since nonspecific effects could occur at the 
concentrations we chose, we tested each inhibitor at concentrations ranging from 10 nM 
to 10 µM.  There was no inhibition of Fsk-induced IL-6 expression by this range of 
concentrations by any of the inhibitors tested (data not shown).  If anything, these 
inhibitors slightly increased Fsk-induced IL-6 expression.  cAMP-mediated regulation of 
IL-6 expression may involve multiple stimulatory and inhibitory pathways with 
substantial cross talk and redundancy, making it difficult to unravel the steps with 
inhibition of individual intermediate kinases. 
 
 
Activation of the IL-6 promoter by Fsk requires AP-1 and CRE sites 
 
We used promoter analysis as an alternative approach to determine the signaling 
pathways involved in cAMP-mediated IL-6 expression.  BSMC were transfected with 
vectors containing 1168 base pairs of the wild type human IL-6 promoter driving 
expression of the luciferase reporter gene.  We also utilized individual promoter-reporter 
constructs that contained mutations in each of the defined promoter elements in order to 
test which transcriptional site(s) are required for cAMP-mediated expression of IL-6.  
The IL-6 promoter contains 2 AP-1 sites and 1 CRE, C/EBP and NFκB site. Site directed 
mutagenesis prevented transcription factor binding at the indicated site. Mutagenesis of 
the 3’ AP-1 site increased IL-6 production in vehicle- and Fsk-treated BSMC, possibly 
due to regulation by a repressor at this site in the wild type promoter (Figure 5-4).  
Promoter activity was unchanged in the other mutant constructs under basal conditions.  
When stimulated with 1 µM Fsk, luciferase activity was significantly reduced when the 
5’AP-1 or CRE site was mutated as compared to the wild type promoter (Figure 5-4).  
Mutations to C/EBP or NF-κB did not alter the promoter’s response to Fsk .  For cAMP 
induction of IL-6 in BSMC, 5’AP-1 and CRE sites are essential but C/EBP and NFκB 
sites are not involved.   
 
 
Discussion 
 
At lower cAMP concentrations, Epac-selective and non-selective cAMP analogs 
have similar effects on IL-6 protein production (Figure 5-1).  At higher cAMP 
concentrations, Epac does not contribute to any additional IL-6 response, but PKA 
signaling has a large effect on inducing IL-6 production.  These data indicate a high 
affinity but low efficacy Epac component and a lower affinity but higher efficacy 
contribution from PKA activity.  Stimulation by 1 µM Fsk likely produces intermediate 
cAMP levels that act through both Epac and PKA to induce IL-6 expression.  PKA 
inhibition with H-89 resulted in a small reduction of IL-6 protein in response to 1 µM or 
10 µM Fsk (Figure 5-2), consistent with dual pathways employing Epac or PKA.    
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Figure 5-3. Fsk-induced IL-6 expression in the presence of kinase inhibitors 
qRT-PCR was used to measure IL-6 mRNA in BSMC pretreated with 10 µM of the 
indicated inhibitor prior to 1 µM, 1 h Fsk exposure.  Data are expressed relative to 
vehicle, mean ± SEM, n=3-4.  
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Figure 5-4. Promoter activity of wild type and mutant IL-6 promoter constructs 
Luciferase assays were used to measure promoter activity in BSMC transfected with wild 
type or mutant promoter constructs and exposed to 1 µM Fsk or vehicle for 6 h.  Wild 
type is 1168 base pairs of the human pIL-6 promoter.  Each promoter mutant construct is 
named by the binding site that has been ablated by site directed mutagenesis.  Data are 
expressed as luminescence relative to wild type basal, mean ± SEM, n=11.  * indicates 
p<.05 compared to wild type.  
 46 
The kinase inhibitors that we used to try to understand the signaling intermediates 
involved did not reduce Fsk-induced IL-6 expression in BSMC (Figure 5-3).  It is 
possible that some other pathway is responsible for activating IL-6 expression, or the 
inhibitors that were effective in other cell types may not be appropriate for inhibiting 
these pathways in BSMC.  By the time the signal has been passed from the plasma 
membrane to the nucleus there are many chances for cross-talk and redundancy of 
pathways, and inhibition at a single point may not be enough to prevent induction.  
Another pitfall is that inhibitors are not highly selective.  An alternative approach to 
pharmacological inhibitors is RNA interference, which could produce specific inhibition 
without off-target effects.  The poor transfection efficiency of BSMC limits the utility of 
RNAi in the present studies.  We found that PKA and Epac are involved in cAMP- 
mediated induction of IL-6 in BSMC, but have little insight into the downstream effectors 
that are involved in the signal transduction pathways leading to activation of transcription 
at CRE and AP-1 promoter sites. 
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CHAPTER 6.    FINAL DISCUSSION AND FUTURE DIRECTIONS  
 
 
AC Isoform-Specific Responses 
 
This work represents the first demonstration of AC isoform-specific control of 
gene regulation.  Previous studies have defined cAMP signaling compartments in near-
membrane events or regulation of proximal intracellular signals, but no other work of 
which we are aware has demonstrated cAMP compartments regulating specific genes.  
AC2 contributes to a signaling compartment that selectively induces IL-6 in BSMC.  
AC6-derived cAMP is involved in regulation of other genes, including SST, which it 
selectively regulates, but it does not influence IL-6 expression.  Differences in AC 
regulation, localization, and associations with other proteins allow AC isoforms to create 
unique cAMP pools with diffusion constrained by activity of PDE.  Through activation of 
Epac and PKA, cAMP produced by AC2 signals to the nucleus and induces IL-6 
expression via CRE and AP-1 promoter elements.   
 
Inherent differences in regulation of AC2 and AC6 could be one contributor to 
AC2 selective IL-6 enhancement.  AC2 is activated by PKC, but AC6 is inhibited by this 
kinase (Jacobowitz and Iyengar 1994; Lai et al. 1999).  The ability of ATPɣS and NECA 
to induce IL-6 without significant global cAMP increase (Figure 4-3) could be explained 
by activation of Gαq-coupled receptors, which stimulate a direct PKC activation of AC2.  
These molecules may all exists as part of a complex with AKAP79 as recently described 
by Shen and Cooper (2013).  Using plasma membrane targeted Epac2 FRET-based 
cAMP sensors along with molecular and pharmacological approaches, they showed that 
activation of muscarinic receptors leads to the receptor’s association with AKAP79 in 
HEK-293 cells.  AKAP79 forms a complex containing the receptor, AC2, PKC, PKA, 
and PDE4.  This complex results in cAMP signals that are confined in space and time.  
Upon stimulation of the muscarinic receptor, PKC activates AC2 (a unique feature of this 
class of AC isoforms).  The cAMP produced by AC2 is short-lived since it activates 
PDE4 activity via PKA, and all components are kept in close association by AKAP79 
(Shen and Cooper 2013).  With such tightly controlled cAMP production and 
degradation, downstream effectors must be in close proximity to the AC in this case.   
 
It is likely that AC6 is also part of signaling complexes containing PDE.  PDE4 
appears to play a role in preventing cAMP produced by AC6 from inducing IL-6 
expression.  When we treated BSMC with the PDE4-selective inhibitor rolipram, 
overexpression of AC6 significantly increased IL-6 production, even at basal AC activity 
(with no addition of Fsk, data not shown).  The AKAP gravin orchestrates a complex 
with PDE4 to restrict cAMP to the membrane region (Willoughby et al. 2006).  Given 
that gravin is expressed in airway smooth muscle one might hypothesize that this 
complex acts to restrict the AC6 signaling compartment (Horvat et al. 2012).  Further 
work should seek to define all the proteins associated with the AC isoforms natively 
expressed in BSMC and uncover cellular responses mediated by these different 
complexes.   
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Downstream Signaling Pathways 
 
Our data indicate that AC2-derived cAMP activates PKA and Epac (Figure 5-1), 
which are both involved in regulating IL-6 expression.  At low levels of cAMP, Epac is 
important for transducing the signal, and at higher cAMP levels PKA plays a 
predominant role.  These responses may reflect different sensitivities of PKA and Epac 
for cAMP or may also be reflective of how these two effectors participate in this specific 
cAMP compartment.  Further studies are needed to fully understand the different roles of 
PKA and Epac.   
 
Measures of bulk intracellular cAMP levels are not correlated with the amount of 
IL-6 produced (Figures 4-3 and 4-4).  Different receptors that stimulated both cAMP 
production and IL-6 did not show a clear relationship between cAMP levels and IL-6.  In 
some cases, this could be explained by activation of other GPCR that stimulate Gαq and 
PKC.  However, Gαs-Fsk synergism using only Gαs-coupled receptors led to increased 
cAMP production with no further increase in IL-6 production.  It is possible that there is 
a threshold after which additional cAMP has no ability to further increase IL-6 
expression.  Alternatively, a cAMP compartment model could also explain the lack of 
correlation with large amounts of cAMP.  If cAMP is not produced in the right location, 
it may be unable to activate the pathways that enhance IL-6 expression. Further studies 
that can detect cAMP produced in distinct subcellular compartments are needed to 
understand if such pools of cAMP exist. 
   
We sought to determine which downstream kinases are involved in induction of 
IL-6 expression with the intent of determining if they are differentially activated when 
AC2 or AC6 is overexpressed and activated.  From the work of others it is apparent that 
cAMP-mediated induction of IL-6 occurs through different pathways based on the cell-
type and stimulus.  We used pharmacological inhibitors of three kinases that are 
associated with cAMP-mediated induction of IL-6 in different cell-types.  GF109203X 
(PKC inhibitor), SB202190 (p38 MAPK inhibitor), and wortmanin (PI3K inhibitor) did 
not inhibit IL-6 expression in response to Fsk, even when a range of concentrations was 
tested (Figure 5-3).  These kinases that were required for IL-6 induction in other cells are 
not essential for Fsk-induced IL-6 production in BSMC.  In fact, our data imply that these 
pathways may tonically inhibit the induction of IL-6.  There also may be significant 
crosstalk among signaling pathways, so inhibition of a single intermediate does not 
prevent signaling to the nucleus and induction of IL-6 expression.  PKC, PI3K or p38 
could be part of the signaling cascade that links surface receptors to CRE and AP-1 sites 
of the IL-6 promoter, but other pathways predominate when one component is inhibited. 
A schematic of the possible signal transduction pathways connecting activation of AC2 to 
induction of IL-6 expression is shown in Figure 6-1. 
 
 
RNA Stabilization 
 
 Throughout this work, we focused on AC2-specific enhancement of induction of 
IL-6 transcription.  The ability of cAMP to regulate gene expression through CRE and 
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Figure 6-1. cAMP-mediated induction of IL-6 in BSMC
Green circles represent cAMP and purple ovals represent downstream effectors.  
Following stimulation by Fsk or GPCR agonists, AC2-derived cAMP activates Epac and 
PKA in a signaling compartment that allows transduction of the signal to the nucleus and 
induction of transcription of IL-6.  PDE prevent AC6-derived cAMP from activating the 
necessary intermediates for inducing IL-6 expression.  cAMP stimulates IL-6 expression 
through AP-1 and CRE sites.  PKA-phosphorylated CREB can activate transcription 
AP-1 and CRE sites, and CREB can also be phosphorylated by kinases PKC, calmodulin 
kinase, and RSK2 (Wen et al. 2010).  Transcription at AP-1 sites can be stimulated by 
Fos/Jun through MAPK signaling pathways.  There are likely many signaling pathways 
driving IL-6 expression in response to cAMP.    
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AP-1 promoter elements is well established (Montminy 1997).  However, careful 
examination of all the data from promoter activity, mRNA levels, and protein production 
it becomes apparent that AC2 might also act to stabilize IL-6 mRNA and not just impact 
promoter activation and transcription of IL-6.  In control cells Fsk induces expression of 
IL-6 mRNA.  It increases promoter activity by approximately 3-fold, mRNA by 6.5-fold 
at 1h, and protein by 2-fold at 24 h (Figures 5-4 and 3-6).  When AC2 is overexpressed, 
IL-6 mRNA is increased 77-fold over cells with endogenous AC expression following 
exposure to 1-µM Fsk for 24 h (Figure 3-1).  At 1 h, the effect of AC2 overexpression on 
Fsk-induced IL-6 mRNA levels is less robust, with only a doubling of IL-6 mRNA 
compared to control (Figure 3-7).  The effect of AC2 overexpression on IL-6 abundance 
is largest at the level of mRNA and has a smaller impact on promoter activation and 
protein production, at least with the methods we have used.  cAMP certainly does induce 
transcription of IL-6 in BSMC, but the enhanced response with overexpression and 
activation of AC2 may also be due to activity that stabilizes IL-6 RNA. 
 
For some genes cAMP has been shown to increase mRNA levels via two distinct 
mechanisms: increasing the rate of transcription and acting to reduce degradation of 
transcripts (Hod and Hanson 1988).  cAMP-mediated stabilization of lactate 
dehydrogenase (LDH) A subunit mRNA involves binding of a complex of PKA-
phosphorylated proteins to the cAMP-stabilizing region (CSR) in the 3’-untranslated 
region.  The formation of the RNA stabilizing complex requires AKAP95, so AC 
isoform-specific interactions are likely involved in this process too (Jungmann and 
Kiryukhina 2005).  Future studies should determine the stability of IL-6 transcripts in 
control and AC overexpressing BSMC to see if AC2-derived cAMP specifically 
stabilizes IL-6 mRNA.  Addition of a transcription inhibitor such as Actinomycin D 
following Fsk exposure would allow comparisons of IL-6 stability in control and AC 
overexpressing cells.  
 
 
Changes in Disease 
 
BSMC from an asthmatic patient had basal levels of IL-6 mRNA that were 
3-times higher than BSMC from a non-asthmatic donor (Figure 3-11).  When BSMC 
from the asthmatic donor were treated with 1 µM Fsk, there was no increase in IL-6 
mRNA compared to those cells untreated.  In non-asthmatic BSMC treated at the same 
time, Fsk caused a 2.6-fold increase in IL-6 mRNA levels.  There could be changes in the 
cAMP signaling compartments or in downstream effector pathways that result from the 
disease.  BSMC from asthmatics are known to have changes in the expression of at least 
one C/EBP isoform, which results in higher IL-6 expression in response to rhinovirus 
infection (Oliver et al. 2006). 
 
While we observed differences in untreated and Fsk-induced IL-6 expression by 
BSMC from normal versus asthmatic donors, this study must be repeated with additional 
donors to confirm the differences are due to asthma.  Future work should examine 
whether there are differences in relative expression and activity of different AC isoforms 
among individuals and in disease.  Studies to characterize the AC isoforms expressed, 
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their localization, and relative activities should be repeated in diseased BSMC to 
determine if there are any intrinsic differences in the cAMP signaling compartments of 
asthmatic BSMC. 
 
 
Phosphoproteomics 
 
The project described here has provided as many questions as answers.  We are 
the first to show AC isoform-specific differences in regulation of gene expression, but 
have little insight into the mechanistic details behind this phenomenon.  By the time a 
cAMP-mediated signal has reached the nucleus there have been many opportunities for 
stimulatory and inhibitory signaling and cross talk among signaling pathways, which 
make it difficult to trace an AC2-derived cAMP signal all the way to the IL-6 promoter.  
Future work will look at differences downstream of individual AC isoforms that are more 
proximal to cAMP production.   
 
We are currently awaiting results from a phosphoproteomics study to identify differences 
in phosphorylation patterns when different AC isoforms are overexpressed and activated 
in BSMC.  We used stable isotope labeling by amino acids in cell culture (SILAC) to 
prepare samples for quantitative phosphoproteomic analysis.  Figure 6-2 illustrates a 
sample SILAC workflow.  SILAC involves culturing two groups of cells in parallel in 
custom media containing isotope labeled arginine and lysine.  The first group is grown in 
medium with unlabeled, “light” amino acids.  The second group is grown in medium with 
arginine and lysine containing exclusively “heavy” non-radioactive 13C and 15N.  Cells 
are grown in the “light” or “heavy” medium for at least 5 passages, which results in 
complete incorporation of these amino acids and all proteins in the cell are isotopically 
labeled (Ong and Mann 2006).  For our study lacZ, AC2, or AC6 overexpressing BSMC 
grown in “light” medium were treated with 1 µM Fsk for 10 min to stimulate protein 
phosphorylation.  The corresponding cells in “heavy” medium were vehicle-treated.  
Following treatment, cells were lysed in a buffer containing protease and phosphatase 
inhibitors.  Total protein in sonicated lysate was determined by BCA protein assay, and 
equal amounts of protein from vehicle- and Fsk- treated samples from cells 
overexpressing the same AC were combined.  Samples were sent to the Mass 
Spectrometry and Proteomics Facility at Johns Hopkins for phosphoprotein enrichment 
and mass spectrometry analysis.  Analysis of these samples will identify the 
phosphoproteins increased in response to Fsk treatment, and AC overexpressing cells will 
be compared to control BSMC.  Isotope labeling allows direct comparison between 
vehicle and Fsk-treated cells, since the two samples are combined equally and prepared  
and analyzed simultaneously.  Proteins in lysate of Fsk-treated cells are “light” at every 
lysine and arginine, so the mass to charge ratio of all trypsin-digested peptides from Fsk-
treated cells will be shifted to the left compared to “heavy” peptides from vehicle-treated 
cells (see Figure 6-2).  Relative intensities of each peptide can be compared to determine 
whether cells with native AC expression and overexpressing AC2 or AC6 display 
increased phosphorylation of that protein in response to 1 µM Fsk.  The relative ratios of 
intensity for different proteins can be compared in lacZ, AC2, and AC6 overexpressing 
cells to determine if phosphorylation patterns differ with overexpression and activation of  
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Figure 6-2. SILAC experimental setup 
(a)  Adaptation phase: “heavy” amino acids are incorporated over time with 100% 
incorporation after five doublings.  (b) Experimental phase:  Following treatment cells 
are lysed and combined 1:1 based on total protein.  Samples are fractionated and 
analyzed by mass spectrometry.  m/z of peptides from cells grown in “heavy” medium 
are shifted to the right.  Relative intensity of “heavy” to “light” peak gives relative 
abundance of peptide in treated compared to control samples.  
 
Reprinted with permission.  ???????? ???? ??????????????????????????????????????
????????????????????????????????????????????????????????? ???????????????????????????
???????????????????????????????? 
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individual AC isoforms.  Results from the SILAC phosphoproteomics study may provide 
insight into signaling intermediates activated by AC2 that could induce IL-6.  Results will 
also be a starting point for uncovering additional AC isoform-specific cellular responses 
in BSMC. 
 
 
AC Isoform-Specific Regulation of Other Genes 
 
This project primarily focused on regulation of IL-6, but the PCR array data 
include other genes that are differentially regulated by individual AC isoforms that could 
be of interest in regard to cAMP signaling compartments and human health (Table A-1).  
With more information on the phosphorylation patterns downstream of individual AC 
from our phosphoproteomics study, pathways linking specific AC isoforms to gene 
regulation may become apparent.   Another gene that appears to be specifically regulated 
by AC2-derived cAMP is prostaglandin-endoperoxide synthase 2, also known as 
cyclooxygenase 2 (COX-2).  COX enzymes catalyze the first step in conversion of 
aracidonic acid to prostanoids, and are important in the pathogenesis of several 
inflammatory diseases (Smith et al. 2000).  COX-1 is constitutively expressed, but 
COX-2 is inducible, and its expression is upregulated in inflammatory diseases and many 
types of cancer (Vane et al. 1998).  IL-1β is one of the proinflammatory cytokines present 
at higher levels in asthmatic airway, and it is one inducer of COX-2 expression in BSMC 
(Pang and Knox 1997).  COX-2 can also be induced by PGE2, one product of COX-
mediated arachadonic acid metabolism, via cAMP signaling pathways (Faour et al. 
2008).  The pathologic consequences of COX-2 induction can be appreciated by 
observing the beneficial anti-inflammatory effects of COX-2 selective inhibitors such as 
Celecoxib (Celobrex) for treatment of chronic inflammation in patients with osteoarthritis 
and rheumatoid arthritis (Vane et al. 1998; FitzGerald and Patrono 2001).    
 
Work from our lab has shown that cAMP-mediated cellular responses can be 
regulated by specific AC isoforms.  This project has demonstrated that individual AC 
isoforms regulate expression of some cAMP-responsive genes.  One gene that is of 
particular interest in the pathogenesis of asthma is the pro-inflammatory cytokine IL-6, 
which is induced by AC2- but not AC6-derived cAMP.  βAR agonists that are used to 
treat asthma may induce IL-6 via AC2 activity.  As more is learned about 
compartmentation of cAMP signaling and attributes of AC isoform-specific 
pharmacological tools, individual AC isoforms have the potential to become therapeutic 
targets.  Our SILAC study could add greatly to the field as it may identify specific 
patterns of kinase activity downstream of individual AC isoforms in BSMC.  
Pharmaceuticals target GPCR for treatment of many diseases through activation of cAMP 
signaling pathways.  Receptors can be promiscuous in their coupling, allowing activation 
of various unintended pathways that can worsen conditions the agonists are meant to 
treat.  Targeting AC directly would allow activation of cAMP signaling pathways without 
the chance of Gαi or Gαq activation.  Work such as ours may allow even more precise 
targeting of therapeutics by identifying the individual AC isoforms and cAMP signaling 
compartments that contribute to beneficial responses for treatment of disease without 
activation of undesirable pathways and adverse effects.  
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APPENDIX.  PCR ARRAYS  
 
 
Table A-1. Fsk-induced gene regulation in AC overexpressing BSMC compared to control BSMC 
 
  AC2  AC3  AC6 
Gene 
 
 
Description Fold 
Change 
SEM  Fold 
Change 
SEM  Fold 
Change 
SEM 
ADRB1 Adrenergic, beta-1-, 
receptor 
-0.445 0.956  -0.302 0.872  1.496 0.152 
AHR Aryl hydrocarbon receptor 1.458 1.595  -1.276 1.189  -1.957 1.673 
AMD1 Adenosylmethionine 
decarboxylase 1 
1.040 1.421  -2.709 2.176  -2.241 2.075 
AREG Amphiregulin 3.743 2.157  1.099 2.588  10.334 4.347 
ATF3 Activating transcription 
factor 3 
2.749 1.071  -1.074 1.261  -2.488 0.733 
BCL2 B-cell CLL/lymphoma 2 0.534 1.124  -1.454 0.368  0.698 1.064 
BDNF Brain-derived neurotrophic 
factor 
0.864 1.048  -1.130 1.347  -0.367 1.123 
BRCA1 Breast cancer 1, early onset 0.849 1.316  -0.459 0.808  -2.474 0.124 
CALB1 Calbindin 1, 28kDa -0.445 0.956  -0.315 0.880  1.366 0.213 
CALB2 Calbindin 2 -0.876 1.215  0.393 0.708  0.559 0.925 
CALM1 Calmodulin 1 
(phosphorylase kinase, 
delta) 
1.772 0.194  -0.774 1.043  -1.859 1.759 
CALR Calreticulin 0.634 1.049  -0.240 1.354  -6.404 6.629 
CCNA1 Cyclin A1 1.806 1.753  0.855 1.446  -1.200 1.267 
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Table A-1. (Continued) 
 
  AC2  AC3  AC6 
Gene 
 
 
Description Fold 
Change 
SEM  Fold 
Change 
SEM  Fold 
Change 
SEM 
CCND1 Cyclin D1 0.608 1.234  -1.668 1.467  -3.416 1.452 
CDK5 Cyclin-dependent kinase 5 0.580 1.385  -1.828 1.691  -1.970 0.534 
CDKN2B Cyclin-dependent kinase 
inhibitor 2B (p15, inhibits 
CDK4) 
2.161 0.534  -1.101 1.354  -2.088 0.364 
CGA Glycoprotein hormones, 
alpha polypeptide 
0.412 0.886  0.415 0.776  0.472 0.964 
CHGA Chromogranin A 
(parathyroid secretory 
protein 1) 
-0.450 0.958  -0.315 0.880  1.480 0.155 
CNN1 Calponin 1, basic, smooth 
muscle 
-1.138 1.204  -1.691 0.144  -1.391 0.173 
CREB1 CAMP responsive element 
binding protein 1 
0.449 1.351  -0.946 1.042  -0.813 0.927 
CREM CAMP responsive element 
modulator 
0.864 1.433  -0.939 1.242  1.562 0.104 
CTF1 Cardiotrophin 1 0.297 0.860  -0.664 0.973  -2.368 0.784 
CYR61 Cysteine-rich, angiogenic 
inducer, 61 
1.121 1.233  0.378 0.892  -2.096 0.346 
DDIT3 DNA-damage-inducible 
transcript 3 
1.856 0.485  0.468 0.875  0.785 1.794 
DUSP1 Dual specificity 
phosphatase 1 
3.385 2.744  -1.144 1.823  -0.839 1.644 
EGR1 Early growth response 1 3.694 2.382  -0.188 1.958  -2.223 1.977 
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Table A-1. (Continued) 
 
  AC2  AC3  AC6 
Gene 
 
 
Description Fold 
Change 
SEM  Fold 
Change 
SEM  Fold 
Change 
SEM 
EGR2 Early growth response 2 1.223 1.232  -0.315 0.880  1.527 0.151 
ENO2 Enolase 2 (gamma, 
neuronal) 
0.791 1.138  -2.244 1.953  -1.607 0.201 
FGF6 Fibroblast growth factor 6 -0.445 0.956  -0.315 0.880  1.366 0.213 
FOS FBJ murine osteosarcoma 
viral oncogene homolog 
3.736 1.400  -0.666 2.957  3.687 2.110 
FOSB FBJ murine osteosarcoma 
viral oncogene homolog B 
0.430 1.613  -0.602 0.854  -0.433 0.847 
GCG Glucagon -0.445 0.956  -0.315 0.880  1.366 0.213 
GEM GTP binding protein 
overexpressed in skeletal 
muscle 
0.406 1.102  -1.401 1.323  -0.361 0.994 
GIPR Gastric inhibitory 
polypeptide receptor 
-2.301 0.570  -0.739 0.936  -0.791 0.956 
HK2 Hexokinase 2 0.168 0.985  -1.086 1.211  -0.717 0.883 
HSPA4 Heat shock 70kDa protein 
4 
-0.491 0.811  -1.689 0.571  -2.123 0.620 
HSPA5 Heat shock 70kDa protein 
5 (glucose-regulated 
protein, 78kDa) 
2.143 2.234  -1.599 1.515  -1.335 1.195 
IL2 Interleukin 2 -0.445 0.956  -0.315 0.880  1.366 0.213 
IL6 Interleukin 6 (interferon, 
beta 2) 
77.159 50.029  0.115 1.667  -0.469 0.747 
INHBA Inhibin, beta A 2.066 1.850  -1.135 1.072  0.462 0.758 
 73 
Table A-1. (Continued) 
 
  AC2  AC3  AC6 
Gene 
 
 
Description Fold 
Change 
SEM  Fold 
Change 
SEM  Fold 
Change 
SEM 
JUNB Jun B proto-oncogene 0.721 1.078  -1.579 1.499  -1.956 0.516 
JUND Jun D proto-oncogene 0.171 1.050  -2.122 0.706  -0.787 1.003 
KCNA5 Potassium voltage-gated 
channel, shaker-related 
subfamily, member 5 
-0.445 0.956  -0.315 0.880  1.366 0.213 
LDHA Lactate dehydrogenase A -0.486 1.901  -1.323 1.239  0.300 0.815 
MAF V-maf musculoaponeurotic 
fibrosarcoma oncogene 
homolog (avian) 
-2.022 0.453  -1.092 1.114  -0.290 0.865 
MIF Macrophage migration 
inhibitory factor 
(glycosylation-inhibiting 
factor) 
0.268 1.040  -0.595 0.912  1.283 0.139 
NCAM1 Neural cell adhesion 
molecule 1 
-0.445 0.956  -0.315 0.880  1.366 0.213 
NF1 Neurofibromin 1 -1.347 0.156  0.187 0.991  -1.265 0.163 
NOS2 Nitric oxide synthase 2, 
inducible 
-0.445 0.956  -0.315 0.880  1.366 0.213 
NPY Neuropeptide Y 0.499 0.875  -0.501 0.798  1.364 0.078 
NR4A2 Nuclear receptor subfamily 
4, group A, member 2 
6.710 4.372  -0.419 1.573  2.391 0.833 
PCK2 Phosphoenolpyruvate 
carboxykinase 2 
(mitochondrial) 
-0.857 1.051  -2.836 0.818  -0.605 1.203 
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Table A-1. (Continued) 
 
  AC2  AC3  AC6 
Gene 
 
 
Description Fold 
Change 
SEM  Fold 
Change 
SEM  Fold 
Change 
SEM 
PCNA Proliferating cell nuclear 
antigen 
0.728 1.291  -1.772 0.314  -2.075 0.511 
PENK Proenkephalin 0.621 1.048  -1.324 0.099  -1.358 0.156 
PER1 Period homolog 1 
(Drosophila) 
-1.256 0.156  -2.071 0.385  -0.439 0.738 
PLAT Plasminogen activator, 
tissue 
0.541 1.753  -1.854 0.592  -1.013 1.131 
PLN Phospholamban -1.680 0.379  -1.536 0.169  0.864 1.161 
PMAIP1 Phorbol-12-myristate-13-
acetate-induced protein 1 
0.617 1.374  -1.889 0.682  1.621 0.026 
POU1F1 POU class 1 homeobox 1 -0.445 0.956  0.384 0.873  1.643 0.317 
POU2AF1 POU class 2 associating 
factor 1 
-0.398 0.939  -0.377 0.770  1.252 0.107 
PPP1R15A Protein phosphatase 1, 
regulatory (inhibitor) 
subunit 15A 
1.046 1.763  -1.422 1.380  -2.866 2.936 
PPP2CA Protein phosphatase 2, 
catalytic subunit, alpha 
isozyme 
0.643 0.896  -2.441 0.794  -1.167 1.202 
PRKAR1A Protein kinase, cAMP-
dependent, regulatory, type 
I, alpha (tissue specific 
extinguisher 1) 
-0.265 1.289  -2.188 0.867  -1.532 0.220 
PRL Prolactin -0.445 0.956  -0.315 0.880  1.757 0.394 
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Table A-1. (Continued) 
 
  AC2  AC3  AC6 
Gene 
 
 
Description Fold 
Change 
SEM  Fold 
Change 
SEM  Fold 
Change 
SEM 
PTGS2 Prostaglandin-
endoperoxide synthase 2 
(prostaglandin G/H 
synthase and 
cyclooxygenase) 
11.294 7.522  -0.737 1.199  2.560 1.004 
RB1 Retinoblastoma 1 1.273 0.096  -0.440 0.973  -0.738 0.965 
S100A12 S100 calcium binding 
protein A12 
-0.445 0.956  -0.315 0.880  1.366 0.213 
S100A6 S100 calcium binding 
protein A6 
-1.747 0.510  -1.924 0.186  -1.225 0.100 
S100G S100 calcium binding 
protein G 
2.214 0.627  -0.157 0.932  2.320 0.790 
SCG2 Secretogranin II -4.204 3.440  -0.944 1.056  2.598 0.189 
SGK1 Serum/glucocorticoid 
regulated kinase 1 
0.397 0.894  -0.743 0.956  1.807 1.732 
SLC18A1 Solute carrier family 18 
(vesicular monoamine), 
member 1 
-0.445 0.956  -0.315 0.880  1.366 0.213 
SOD2 Superoxide dismutase 2, 
mitochondrial 
-1356.5 1369.7  -0.267 0.969  -2.159 2.664 
SRF Serum response factor (c-
fos serum response 
element-binding 
transcription factor) 
0.458 0.864  -0.997 1.083  -0.522 1.215 
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Table A-1. (Continued) 
 
  AC2  AC3  AC6 
Gene 
 
 
Description Fold 
Change 
SEM  Fold 
Change 
SEM  Fold 
Change 
SEM 
SST Somatostatin -0.826 1.466  1.072 1.283  9.737 0.791 
SSTR2 Somatostatin receptor 2 0.363 0.989  -1.342 0.025  2.003 0.487 
STAT3 Signal transducer and 
activator of transcription 3 
(acute-phase response 
factor) 
0.434 0.900  -1.369 0.011  -0.535 0.982 
TACR1 Tachykinin receptor 1 0.441 1.027  -1.600 0.304  0.820 1.353 
TGFB3 Transforming growth 
factor, beta 3 
-0.301 0.831  -1.523 0.295  0.981 1.059 
TH Tyrosine hydroxylase -0.445 0.956  -0.315 0.880  1.366 0.213 
THBS1 Thrombospondin 1 -1.681 0.140  -1.649 0.055  -0.792 0.956 
TNF Tumor necrosis factor -0.445 0.956  -0.315 0.880  1.366 0.213 
VCL Vinculin -0.340 1.321  -0.570 1.212  0.836 1.330 
VIP Vasoactive intestinal 
peptide 
1.910 0.520  -1.575 0.514  0.169 1.120 
 
Notes:  BSMC were treated with 1 µM Fsk for 24 h.  Gene expression is expressed as fold change with respect to lacZ. 
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Table A-2. Fsk-induced gene regulation in AC overexpressing HEK compared to 
control HEK 
 
Gene 
 
Description AC2 
 
AC6 
ADRB1 Adrenergic, beta-1-, receptor 1.879 1.3472 
AHR Aryl hydrocarbon receptor 1.2142 1.4241 
AMD1 Adenosylmethionine decarboxylase 1 1.257 -1.0425 
AREG Amphiregulin 1.014 1.4948 
ATF3 Activating transcription factor 3 1.1892 1.366 
BCL2 B-cell CLL/lymphoma 2 1.0718 1.1173 
BDNF Brain-derived neurotrophic factor 1.4743 1.0644 
BRCA1 Breast cancer 1, early onset 1.0792 1.2058 
CALB1 Calbindin 1, 28kDa 1.5583 -1.057 
CALB2 Calbindin 2 1.5583 -1.057 
CALM1 Calmodulin 1 (phosphorylase kinase, 
delta) 
1.5583 1.1251 
CALR Calreticulin 1.9453 1.1173 
CCNA1 Cyclin A1 1.3947 1.6586 
CCND1 Cyclin D1 -148.0561 -1.4142 
CDK5 Cyclin-dependent kinase 5 1.2226 1.1019 
CDKN2B Cyclin-dependent kinase inhibitor 2B 
(p15, inhibits CDK4) 
1.4044 1.0497 
CGA Glycoprotein hormones, alpha 
polypeptide 
1.1728 1.7654 
CHGA Chromogranin A (parathyroid 
secretory protein 1) 
1.0497 -1.0943 
CNN1 Calponin 1, basic, smooth muscle -1.0718 -3.0951 
CREB1 CAMP responsive element binding 
protein 1 
1.3195 1.2226 
CREM CAMP responsive element modulator 1.2226 1.4845 
CTF1 Cardiotrophin 1 1.9453 -1.4743 
CYR61 Cysteine-rich, angiogenic inducer, 61 2.1435 -1.0644 
DDIT3 DNA-damage-inducible transcript 3 1.7654 1.879 
DUSP1 Dual specificity phosphatase 1 1.0497 1.0718 
EGR1 Early growth response 1 1.0644 1.0943 
EGR2 Early growth response 2 2.4794 -1.1408 
ENO2 Enolase 2 (gamma, neuronal) -1.0497 -1.6358 
FGF6 Fibroblast growth factor 6 1.7171 -1.057 
FOS FBJ murine osteosarcoma viral 
oncogene homolog 
-1.014 -1.0353 
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Table A-2. (Continued) 
 
Gene 
 
Description AC2 
 
AC6 
FOSB FBJ murine osteosarcoma viral 
oncogene homolog B 
1.1487 1.2924 
GCG Glucagon 1.5583 -1.057 
GEM GTP binding protein overexpressed in 
skeletal muscle 
1.8532 1.6472 
GIPR Gastric inhibitory polypeptide receptor 3.9177 1.3287 
HK2 Hexokinase 2 2 -1.0644 
HSPA4 Heat shock 70kDa protein 4 1.7777 -1 
HSPA5 Heat shock 70kDa protein 5 (glucose-
regulated protein, 78kDa) 
-1.0644 1.6133 
IL2 Interleukin 2 1.5583 -1.057 
IL6 Interleukin 6 (interferon, beta 2) 1.5583 1.6586 
INHBA Inhibin, beta A -1.0718 1.9053 
JUNB Jun B proto-oncogene 1.021 -1.6358 
JUND Jun D proto-oncogene 1.3287 -1.5052 
KCNA5 Potassium voltage-gated channel, 
shaker-related subfamily, member 5 
1.5583 -1.057 
LDHA Lactate dehydrogenase A 1.3104 1.7532 
MAF V-maf musculoaponeurotic 
fibrosarcoma oncogene homolog 
(avian) 
1.5157 2.0994 
MIF Macrophage migration inhibitory 
factor (glycosylation-inhibiting factor) 
1.5583 1.8025 
NCAM1 Neural cell adhesion molecule 1 1.6818 2.2658 
NF1 Neurofibromin 1 1.5369 1.6472 
NOS2 Nitric oxide synthase 2, inducible 1.0425 1.3287 
NPY Neuropeptide Y -1.181 1.2746 
NR4A2 Nuclear receptor subfamily 4, group 
A, member 2 
1.1329 1.6358 
PCK2 Phosphoenolpyruvate carboxykinase 2 
(mitochondrial) 
1.057 -1.0792 
PCNA Proliferating cell nuclear antigen 1.0867 1.014 
PENK Proenkephalin 1.057 -1.0497 
PER1 Period homolog 1 (Drosophila) 1.4241 -1.8404 
PLAT Plasminogen activator, tissue 1.5052 1.0425 
PLN Phospholamban 1.1019 1.815 
PMAIP1 Phorbol-12-myristate-13-acetate-
induced protein 1 
1.4845 1.5476 
POU1F1 POU class 1 homeobox 1 1.5911 1.1019 
POU2AF1 POU class 2 associating factor 1 1.3472 -1.3013 
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Table A-2. (Continued) 
 
Gene 
 
Description AC2 
 
AC6 
PPP1R15A Protein phosphatase 1, regulatory 
(inhibitor) subunit 15A 
1.0497 -1.4948 
PPP2CA Protein phosphatase 2, catalytic 
subunit, alpha isozyme 
-1 1.2746 
PRKAR1A Protein kinase, cAMP-dependent, 
regulatory, type I, alpha (tissue 
specific extinguisher 1) 
1.3195 -1.0425 
PRL Prolactin 1.5583 -1.057 
PTGS2 Prostaglandin-endoperoxide synthase 
2 (prostaglandin G/H synthase and 
cyclooxygenase) 
1.1251 1.3947 
RB1 Retinoblastoma 1 1.1975 1.2924 
S100A12 S100 calcium binding protein A12 1.5583 -1.057 
S100A6 S100 calcium binding protein A6 1.5583 1.0943 
S100G S100 calcium binding protein G 3.8637 2.7511 
SCG2 Secretogranin II -1.2483 1.4044 
SGK1 Serum/glucocorticoid regulated kinase 
1 
1.0497 1.9053 
SLC18A1 Solute carrier family 18 (vesicular 
monoamine), member 1 
1.5583 -1.057 
SOD2 Superoxide dismutase 2, 
mitochondrial 
1.1251 1.1728 
SRF Serum response factor (c-fos serum 
response element-binding transcription 
factor) 
1.2226 -1.1567 
SST Somatostatin 1.5583 -1.057 
SSTR2 Somatostatin receptor 2 1.6586 1.434 
STAT3 Signal transducer and activator of 
transcription 3 (acute-phase response 
factor) 
1.0353 1.257 
TACR1 Tachykinin receptor 1 2.042 -1.1096 
TGFB3 Transforming growth factor, beta 3 1.0943 -1.366 
TH Tyrosine hydroxylase 1.5583 -1.057 
THBS1 Thrombospondin 1 1.2226 1.5583 
TNF Tumor necrosis factor 1.5692 4.8568 
VCL Vinculin 1.1173 1.4641 
VIP Vasoactive intestinal peptide 1.8921 4.4691 
 
Notes:  HEK-293 were treated with 1 µM Fsk for 24 h.  Gene expression is expressed as 
fold change with respect to empty pEGFP-n1 vector. 
 
 80 
Table A-3. GPCR expression in BSMC 
 
Gene Description Average 
CP 
 
SD 
LPAR1 Lysophosphatidic acid receptor 1 23.49 0.30 
F2R Coagulation factor II (thrombin) receptor 23.58 0.37 
GPR176 G protein-coupled receptor 176 24.41 0.10 
PDGFRB Platelet-derived growth factor receptor, beta 
polypeptide 
24.76 0.24 
F2RL2 Coagulation factor II (thrombin) receptor-like 
2 
24.92 0.40 
SIGMAR
1 
Sigma non-opioid intracellular receptor 1 25.06 0.21 
FZD1 Frizzled family receptor 1 25.40 0.30 
CCRL1 Chemokine (C-C motif) receptor-like 1 25.82 0.23 
NPR2 Natriuretic peptide receptor B/guanylate 
cyclase B (atrionatriuretic peptide receptor B) 
25.82 0.18 
TM2D1 TM2 domain containing 1 25.85 0.28 
EDNRB Endothelin receptor type B 25.90 0.25 
FZD6 Frizzled family receptor 6 26.00 0.14 
LPHN2 Latrophilin 2 26.01 0.18 
GPRC5A G protein-coupled receptor, family C, group 5, 
member A 
26.02 0.36 
CD97 CD97 molecule 26.06 0.33 
OPN3 Opsin 3 26.06 0.13 
NPR3 Natriuretic peptide receptor C/guanylate 
cyclase C (atrionatriuretic peptide receptor C) 
26.13 0.13 
FZD7 Frizzled family receptor 7 26.29 0.51 
S1PR2 Sphingosine-1-phosphate receptor 2 26.38 0.17 
OPN1SW Opsin 1 (cone pigments), short-wave-sensitive 26.39 0.08 
EDNRA Endothelin receptor type A 26.44 0.29 
CHRM2 Cholinergic receptor, muscarinic 2 26.49 0.42 
S1PR3 Sphingosine-1-phosphate receptor 3 26.53 0.11 
BDKRB1 Bradykinin receptor B1 26.53 0.11 
FZD2 Frizzled family receptor 2 26.61 0.06 
BDKRB2 Bradykinin receptor B2 26.66 0.18 
XPR1 Xenotropic and polytropic retrovirus receptor 
1 
26.74 0.37 
GPR157 G protein-coupled receptor 157 27.04 0.11 
CRCP CGRP receptor component 27.17 0.13 
ELTD1 EGF, latrophilin and seven transmembrane 
domain containing 1 
27.29 0.24 
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Table A-3. (Continued) 
 
Gene Description Average 
CP 
 
SD 
OGFR Opioid growth factor receptor 27.36 0.39 
GPR153 G protein-coupled receptor 153 27.51 0.51 
FZD4 Frizzled family receptor 4 27.54 0.35 
ADORA2
B 
Adenosine A2b receptor 27.61 0.67 
GPR125 G protein-coupled receptor 125 27.62 0.47 
SSTR1 Somatostatin receptor 1 27.62 0.10 
GPR124 G protein-coupled receptor 124 27.68 0.02 
PDGFRL Platelet-derived growth factor receptor-like 27.71 0.66 
PTGER4 Prostaglandin E receptor 4 (subtype EP4) 27.71 0.31 
LEPR Leptin receptor 27.74 0.22 
MRGPRF MAS-related GPR, member F 27.78 0.45 
MRGPR
G 
MAS-related GPR, member G 27.85 0.91 
S1PR1 Sphingosine-1-phosphate receptor 1 27.99 0.94 
NTSR1 Neurotensin receptor 1 (high affinity) 28.20 0.32 
FZD8 Frizzled family receptor 8 28.24 0.46 
HRH1 Histamine receptor H1 28.32 0.45 
CHRM1 Cholinergic receptor, muscarinic 1 28.34 0.83 
PTGFR Prostaglandin F receptor (FP) 28.38 0.25 
GPRC5B G protein-coupled receptor, family C, group 5, 
member B 
28.39 0.13 
GPR161 G protein-coupled receptor 161 28.48 0.06 
GPR37 G protein-coupled receptor 37 (endothelin 
receptor type B-like) 
28.54 0.06 
GPR152 G protein-coupled receptor 152 28.60 0.04 
F2RL1 Coagulation factor II (thrombin) receptor-like 
1 
28.60 0.08 
GPR27 G protein-coupled receptor 27 28.64 0.17 
GPR85 G protein-coupled receptor 85 28.65 0.16 
GPR39 G protein-coupled receptor 39 28.66 0.23 
LPAR3 Lysophosphatidic acid receptor 3 28.67 0.25 
CNR2 Cannabinoid receptor 2 (macrophage) 28.82 0.71 
SMO Smoothened, frizzled family receptor 28.86 0.40 
CXCR7 Chemokine (C-X-C motif) receptor 7 29.00 0.97 
GPR135 G protein-coupled receptor 135 29.03 0.04 
LPAR6 Lysophosphatidic acid receptor 6 29.04 0.01 
GPR173 G protein-coupled receptor 173 29.04 0.20 
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Table A-3. (Continued) 
 
Gene Description Average 
CP 
 
SD 
GPR1 G protein-coupled receptor 1 29.10 0.08 
P2RY11 Purinergic receptor P2Y, G-protein coupled, 
11 
29.13 0.03 
OPRD1 Opioid receptor, delta 1 29.29 1.06 
CASR Calcium-sensing receptor 29.36 1.24 
SSTR4 Somatostatin receptor 4 29.38 0.59 
GPR31 G protein-coupled receptor 31 29.56 1.34 
ADRA1D Adrenergic, alpha-1D-, receptor 29.62 0.64 
GPR162 G protein-coupled receptor 162 29.64 0.16 
GABBR1 Gamma-aminobutyric acid (GABA) B 
receptor, 1 
29.65 0.03 
F2RL3 Coagulation factor II (thrombin) receptor-like 
3 
29.71 0.78 
GPR75 G protein-coupled receptor 75 29.78 0.25 
LPHN1 Latrophilin 1 29.85 0.18 
ADRB2 Adrenergic, beta-2-, receptor, surface 29.90 0.56 
GPR37L1 G protein-coupled receptor 37 like 1 29.96 0.52 
GPR68 G protein-coupled receptor 68 30.09 0.35 
NPR1 Natriuretic peptide receptor A/guanylate 
cyclase A (atrionatriuretic peptide receptor A) 
30.15 0.77 
HTR7 5-hydroxytryptamine (serotonin) receptor 7 
(adenylate cyclase-coupled) 
30.17 0.91 
CHRM4 Cholinergic receptor, muscarinic 4 30.22 0.46 
GPR12 G protein-coupled receptor 12 30.23 0.11 
BAI2 Brain-specific angiogenesis inhibitor 2 30.26 0.26 
GPR55 G protein-coupled receptor 55 30.37 0.07 
CCBP2 Chemokine binding protein 2 30.38 1.15 
GPR126 G protein-coupled receptor 126 30.40 0.41 
GPR111 G protein-coupled receptor 111 30.53 0.71 
GPR97 G protein-coupled receptor 97 30.56 0.47 
LPAR5 Lysophosphatidic acid receptor 5 30.61 0.18 
MRGPRD MAS-related GPR, member D 30.65 0.22 
TBXA2R Thromboxane A2 receptor 30.66 0.12 
CCR3 Chemokine (C-C motif) receptor 3 30.68 0.62 
GPR63 G protein-coupled receptor 63 30.70 0.16 
PTGIR Prostaglandin I2 (prostacyclin) receptor (IP) 30.73 0.17 
NTSR2 Neurotensin receptor 2 30.76 0.08 
GPR78 G protein-coupled receptor 78 30.83 0.34 
HTR3A 5-hydroxytryptamine (serotonin) receptor 3A 31.12 0.91 
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Table A-3. (Continued) 
 
Gene Description Average 
CP 
 
SD 
FZD5 Frizzled family receptor 5 31.18 1.01 
GPR56 G protein-coupled receptor 56 31.20 0.13 
GPR3 G protein-coupled receptor 3 31.26 0.35 
DRD4 Dopamine receptor D4 31.28 0.41 
PTGER3 Prostaglandin E receptor 3 (subtype EP3) 31.28 0.03 
RXFP3 Relaxin/insulin-like family peptide receptor 
3 
31.29 0.37 
CCR7 Chemokine (C-C motif) receptor 7 31.33 0.18 
NMUR1 Neuromedin U receptor 1 31.34 0.74 
TAAR5 Trace amine associated receptor 5 31.35 0.48 
MRGPRE MAS-related GPR, member E 31.37 0.12 
LTB4R Leukotriene B4 receptor 31.40 0.20 
GPR26 G protein-coupled receptor 26 31.49 0.08 
GPR65 G protein-coupled receptor 65 31.51 0.71 
GPR44 G protein-coupled receptor 44 31.59 0.18 
AVPR1A Arginine vasopressin receptor 1A 31.63 0.23 
GPR182 G protein-coupled receptor 182 31.63 0.28 
CRHR1 Corticotropin releasing hormone receptor 1 31.64 0.16 
CALCRL Calcitonin receptor-like 31.76 0.08 
GNRHR Gonadotropin-releasing hormone receptor 31.76 0.74 
XCR1 Chemokine (C motif) receptor 1 31.79 0.19 
CX3CR1 Chemokine (C-X3-C motif) receptor 1 31.79 0.34 
GPR160 G protein-coupled receptor 160 31.81 0.22 
RHO Rhodopsin 31.81 0.54 
CCR10 Chemokine (C-C motif) receptor 10 31.82 0.04 
PTGER1 Prostaglandin E receptor 1 (subtype EP1), 
42kDa 
31.82 0.71 
VIPR2 Vasoactive intestinal peptide receptor 2 31.83 0.06 
GPR133 G protein-coupled receptor 133 31.86 0.18 
NMUR2 Neuromedin U receptor 2 31.87 0.42 
NPSR1 Neuropeptide S receptor 1 31.87 0.88 
GPRC5D G protein-coupled receptor, family C, group 
5, member D 
31.88 0.38 
NPBWR1 Neuropeptides B/W receptor 1 31.91 0.30 
P2RY2 Purinergic receptor P2Y, G-protein coupled, 
2 
31.94 0.99 
CELSR3 Cadherin, EGF LAG seven-pass G-type 
receptor 3 (flamingo homolog, Drosophila) 
31.99 0.06 
ADORA1 Adenosine A1 receptor 32.01 0.30 
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Table A-3. (Continued) 
 
Gene Description Average 
CP 
 
SD 
OPRK1 Opioid receptor, kappa 1 32.02 0.28 
CXCR6 Chemokine (C-X-C motif) receptor 6 32.06 0.37 
CELSR2 Cadherin, EGF LAG seven-pass G-type 
receptor 2 (flamingo homolog, Drosophila) 
32.07 0.11 
ADRA1A Adrenergic, alpha-1A-, receptor 32.09 0.51 
GPR179 G protein-coupled receptor 179 32.12 0.11 
P2RY6 Pyrimidinergic receptor P2Y, G-protein 
coupled, 6 
32.20 0.37 
S1PR5 Sphingosine-1-phosphate receptor 5 32.26 0.42 
GABBR2 Gamma-aminobutyric acid (GABA) B 
receptor, 2 
32.29 0.95 
ADRA2A Adrenergic, alpha-2A-, receptor 32.32 0.57 
GPR174 G protein-coupled receptor 174 32.32 0.17 
GPR35 G protein-coupled receptor 35 32.33 0.68 
GPR62 G protein-coupled receptor 62 32.34 0.40 
ADRA1B Adrenergic, alpha-1B-, receptor 32.35 0.54 
GPR183 G protein-coupled receptor 183 32.39 0.11 
GPR21 G protein-coupled receptor 21 32.41 0.11 
OPRM1 Opioid receptor, mu 1 32.42 0.43 
CCR4 Chemokine (C-C motif) receptor 4 32.45 0.51 
GPR142 G protein-coupled receptor 142 32.45 0.25 
ADORA2
A 
Adenosine A2a receptor 32.47 0.01 
HTR1B 5-hydroxytryptamine (serotonin) receptor 1B 32.48 0.89 
GPR18 G protein-coupled receptor 18 32.54 0.50 
MTNR1A Melatonin receptor 1A 32.56 0.01 
PPYR1 Pancreatic polypeptide receptor 1 32.59 0.04 
LTB4R2 Leukotriene B4 receptor 2 32.61 0.16 
SORCS1 Sortilin-related VPS10 domain containing 
receptor 1 
32.65 0.28 
P2RY14 Purinergic receptor P2Y, G-protein coupled, 
14 
32.68 0.76 
GPR45 G protein-coupled receptor 45 32.72 1.00 
TACR3 Tachykinin receptor 3 32.75 0.06 
GPR101 G protein-coupled receptor 101 32.81 0.15 
GPR64 G protein-coupled receptor 64 32.92 0.84 
PTGDR Prostaglandin D2 receptor (DP) 32.92 1.05 
GPR52 G protein-coupled receptor 52 32.93 0.35 
PTH1R Parathyroid hormone 1 receptor 32.94 0.09 
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LPAR2 Lysophosphatidic acid receptor 2 32.95 0.47 
CHRM3 Cholinergic receptor, muscarinic 3 33.01 0.69 
SSTR2 Somatostatin receptor 2 33.03 1.60 
GHRHR Growth hormone releasing hormone receptor 33.06 0.15 
GPR77 G protein-coupled receptor 77 33.09 0.08 
CCKBR Cholecystokinin B receptor 33.12 1.15 
HCAR1 Hydroxycarboxylic acid receptor 1 33.12 0.45 
NPBWR2 Neuropeptides B/W receptor 2 33.17 0.65 
NPFFR1 Neuropeptide FF receptor 1 33.17 0.16 
TAAR2 Trace amine associated receptor 2 33.18 1.00 
GPR19 G protein-coupled receptor 19 33.20 1.78 
PTAFR Platelet-activating factor receptor 33.28 0.05 
GPR149 G protein-coupled receptor 149 33.33 1.10 
PROKR2 Prokineticin receptor 2 33.33 1.58 
GPR83 G protein-coupled receptor 83 33.35 0.29 
TRHR Thyrotropin-releasing hormone receptor 33.39 0.86 
ADRB1 Adrenergic, beta-1-, receptor 33.39 0.81 
GPR32 G protein-coupled receptor 32 33.45 0.32 
AVPR2 Arginine vasopressin receptor 2 33.55 0.15 
GPR115 G protein-coupled receptor 115 33.59 0.69 
GALR2 GALANIN RECEPTOR 2 33.61 0.72 
FZD9 Frizzled family receptor 9 33.63 0.95 
GPR148 G protein-coupled receptor 148 33.66 0.16 
HCAR2 Hydroxycarboxylic acid receptor 2 33.66 0.88 
FFAR2 Free fatty acid receptor 2 33.68 0.64 
MC5R Melanocortin 5 receptor 33.69 1.29 
LPAR4 Lysophosphatidic acid receptor 4 33.72 1.12 
GPR113 G protein-coupled receptor 113 33.73 0.32 
GPR61 G protein-coupled receptor 61 33.86 0.42 
GPR144 G protein-coupled receptor 144 33.87 0.60 
P2RY13 Purinergic receptor P2Y, G-protein coupled, 
13 
33.92 0.27 
LPHN3 Latrophilin 3 33.94 0.25 
S1PR4 Sphingosine-1-phosphate receptor 4 33.94 0.70 
HTR1F 5-hydroxytryptamine (serotonin) receptor 1F 33.96 1.01 
GPR34 G protein-coupled receptor 34 34.01 0.09 
GPR82 G protein-coupled receptor 82 34.14 0.64 
DRD2 Dopamine receptor D2 34.14 0.71 
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O3FAR1 Omega-3 fatty acid receptor 1 34.15 0.04 
MCHR1 Melanin-concentrating hormone receptor 1 34.24 0.77 
GPR84 G protein-coupled receptor 84 34.28 0.67 
P2RY4 Pyrimidinergic receptor P2Y, G-protein 
coupled, 4 
34.29 0.97 
FPR1 Formyl peptide receptor 1 34.37 0.52 
RGR Retinal G protein coupled receptor 34.42 1.29 
P2RY1 Purinergic receptor P2Y, G-protein coupled, 1 34.49 0.73 
TACR1 Tachykinin receptor 1 34.49 1.94 
APLNR Apelin receptor 34.67 1.26 
GCGR Glucagon receptor 34.68 0.04 
GPR6 G protein-coupled receptor 6 34.81 0.23 
LGR5 Leucine-rich repeat containing G protein-
coupled receptor 5 
34.87 0.93 
TAAR9 Trace amine associated receptor 9 
(gene/pseudogene) 
34.87 0.13 
GPBAR1 G protein-coupled bile acid receptor 1 34.89 2.65 
BRS3 Bombesin-like receptor 3 34.89 0.83 
GPRC6A G protein-coupled receptor, family C, group 6, 
member A 
35.08 1.90 
GRM2 Glutamate receptor, metabotropic 2 35.09 1.12 
GPR116 G protein-coupled receptor 116 35.10 0.33 
GRM7 Glutamate receptor, metabotropic 7 35.11 0.30 
GRM1 Glutamate receptor, metabotropic 1 35.12 0.96 
GPR17 G protein-coupled receptor 17 35.22 0.16 
C5AR1 Complement component 5a receptor 1 35.26 0.31 
CCR8 Chemokine (C-C motif) receptor 8 35.37 1.27 
RRH Retinal pigment epithelium-derived rhodopsin 
homolog 
35.38 1.25 
FZD3 Frizzled family receptor 3 35.38 1.05 
GPR119 G protein-coupled receptor 119 35.42 0.51 
CCR9 Chemokine (C-C motif) receptor 9 35.44 1.12 
GPR151 G protein-coupled receptor 151 35.44 0.58 
GPR22 G protein-coupled receptor 22 35.45 4.15 
CCR6 Chemokine (C-C motif) receptor 6 35.57 1.35 
GPR156 G protein-coupled receptor 156 35.60 1.63 
HTR6 5-hydroxytryptamine (serotonin) receptor 6 35.64 0.76 
DARC Duffy blood group, chemokine receptor 35.66 1.05 
GPR123 G protein-coupled receptor 123 35.66 0.14 
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NPFFR2 Neuropeptide FF receptor 2 35.68 0.19 
CXCR5 Chemokine (C-X-C motif) receptor 5 35.74 1.33 
CMKLR1 CHEMOKINE-LIKE RECEPTOR 1 35.97 1.71 
TSHR Thyroid stimulating hormone receptor 36.04 0.53 
CALCR CALCITONIN RECEPTOR 36.08 0.51 
BAI1 Brain-specific angiogenesis inhibitor 1 36.23 0.78 
GPR171 G protein-coupled receptor 171 36.24 2.38 
GRIK3 Glutamate receptor, ionotropic, kainate 3 36.26 0.05 
NPY1R Neuropeptide Y receptor Y1 36.30 0.52 
GPR15 G protein-coupled receptor 15 36.31 0.40 
TAAR6 Trace amine associated receptor 6 36.40 0.64 
CXCR4 Chemokine (C-X-C motif) receptor 4 36.42 0.36 
PRLHR Prolactin releasing hormone receptor 36.42 1.16 
MC4R Melanocortin 4 receptor 36.58 0.16 
GPR112 G protein-coupled receptor 112 36.60 0.06 
GPR139 G protein-coupled receptor 139 36.60 0.25 
OPN5 Opsin 5 36.64 0.62 
GPR50 G protein-coupled receptor 50 36.66 0.23 
NPY2R Neuropeptide Y receptor Y2 36.70 0.04 
GPR87 G protein-coupled receptor 87 36.70 2.73 
GLP2R Glucagon-like peptide 2 receptor 36.79 0.76 
OXGR1 Oxoglutarate (alpha-ketoglutarate) receptor 1 36.97 0.08 
CXCR2 Chemokine (C-X-C motif) receptor 2 37.03 1.14 
PROKR1 Prokineticin receptor 1 37.06 0.43 
P2RY10 Purinergic receptor P2Y, G-protein coupled, 
10 
37.21 0.60 
GPR128 G protein-coupled receptor 128 37.24 0.11 
GALR1 Galanin receptor 1 37.34 3.77 
GPR143 G protein-coupled receptor 143 37.53 1.32 
HRH4 Histamine receptor H4 37.53 3.49 
SSTR3 Somatostatin receptor 3 37.56 0.65 
TAAR1 Trace amine associated receptor 1 37.66 0.49 
MRGPRX
4 
MAS-related GPR, member X4 37.69 2.13 
HTR2C 5-hydroxytryptamine (serotonin) receptor 2C 37.82 0.30 
ADCYAP
1R1 
Adenylate cyclase activating polypeptide 1 
(pituitary) receptor type I 
37.69 0.64 
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A 37.83 3.07 
FZD10 Frizzled family receptor 10 38.04 0.27 
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SORCS3 Sortilin-related VPS10 domain containing 
receptor 3 
38.10 2.69 
MRGPRX
3 
MAS-related GPR, member X3 38.48 2.16 
GRM8 Glutamate receptor, metabotropic 8 38.52 0.54 
ADORA3 Adenosine A3 receptor 38.79 1.72 
MRGPRX
2 
MAS-related GPR, member X2 38.86 1.61 
CYSLTR
1 
Cysteinyl leukotriene receptor 1 38.99 1.44 
HTR4 5-hydroxytryptamine (serotonin) receptor 4 39.02 1.39 
SCTR Secretin receptor 39.07 1.32 
GPR141 G protein-coupled receptor 141 39.27 1.04 
MC2R Melanocortin 2 receptor (adrenocorticotropic 
hormone) 
39.52 0.69 
HTR1A 5-hydroxytryptamine (serotonin) receptor 1A 39.70 0.42 
AGTR2 Angiotensin II receptor, type 2 40.00 0.00 
BAI3 Brain-specific angiogenesis inhibitor 3 40.00 0.00 
CCRL2 Chemokine (C-C motif) receptor-like 2 40.00 0.00 
CYSLTR
2 
Cysteinyl leukotriene receptor 2 40.00 0.00 
DRD5 Dopamine receptor D5 40.00 0.00 
GALR3 Galanin receptor 3 40.00 0.00 
GRM5 Glutamate receptor, metabotropic 5 40.00 0.00 
HCRTR1 Hypocretin (orexin) receptor 1 40.00 0.00 
LHCGR Luteinizing hormone/choriogonadotropin 
receptor 
40.00 0.00 
OPN4 Opsin 4 40.00 0.00 
P2RY12 Purinergic receptor P2Y, G-protein coupled, 
12 
40.00 0.00 
SUCNR1 Succinate receptor 1 40.00 0.00 
QRFPR Pyroglutamylated RFamide peptide receptor 40.00 0.00 
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